<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy - Chan, KKW - 2015 | Cochrane Library</title> <meta content="Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy - Chan, KKW - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010341.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy - Chan, KKW - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010341.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010341.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy" name="citation_title"/> <meta content="Kelvin KW Chan" name="citation_author"/> <meta content="Sunnybrook Health Sciences Centre" name="citation_author_institution"/> <meta content="Anne‐Marie Glenny" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="Jo C Weldon" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="Susan Furness" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="Helen V Worthington" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="Helen Wakeford" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="helen.wakeford@manchester.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010341.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/12/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010341.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010341.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010341.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [therapeutic use]; Antineoplastic Agents [*therapeutic use]; Carcinoma, Squamous Cell [mortality, *therapy]; Cetuximab [therapeutic use]; Cisplatin [therapeutic use]; Docetaxel; ErbB Receptors; Gefitinib; Immunotherapy [adverse effects, *methods]; Lapatinib; Molecular Targeted Therapy [adverse effects, *methods]; Mouth Neoplasms [mortality, *therapy]; Oropharyngeal Neoplasms [mortality, *therapy]; Protein Kinase Inhibitors [therapeutic use]; Protein‐Tyrosine Kinases [antagonists &amp; inhibitors]; Quinazolines [therapeutic use]; Randomized Controlled Trials as Topic; Taxoids [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010341.pub2&amp;doi=10.1002/14651858.CD010341.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WcPhDegp";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010341\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010341\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010341.pub2",title:"Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy",firstPublishedDate:"Dec 1, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Oral Health Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010341.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010341.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010341.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010341.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010341.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010341.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010341.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010341.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010341.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010341.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6791 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010341.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0143"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/appendices#CD010341-sec-0148"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/table_n/CD010341StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/table_n/CD010341StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#CD010341-cr-0002">Kelvin KW Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#CD010341-cr-0003">Anne‐Marie Glenny</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#CD010341-cr-0004">Jo C Weldon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#CD010341-cr-0005">Susan Furness</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#CD010341-cr-0006">Helen V Worthington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information#CD010341-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Helen Wakeford</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information/en#CD010341-sec-0158">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 December 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010341.pub2">https://doi.org/10.1002/14651858.CD010341.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010341-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010341-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010341-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010341-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD010341-abs-0010">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010341-abs-0001" lang="en"> <section id="CD010341-sec-0001"> <h3 class="title" id="CD010341-sec-0001">Background</h3> <p>Oral cancers are the sixth most common cancer worldwide, yet the prognosis following a diagnosis of oral cavity or oropharyngeal cancers remains poor, with approximately 50% survival at five years. Despite a sharp increase in research into molecularly targeted therapies and a rapid expansion in the number of clinical trials assessing new targeted therapies, their value for treating oral cancers is unclear. Therefore, it is important to summarise the evidence to determine the efficacy and toxicity of targeted therapies and immunotherapies for the treatment of these cancers. </p> </section> <section id="CD010341-sec-0002"> <h3 class="title" id="CD010341-sec-0002">Objectives</h3> <p>To assess the effects of molecularly targeted therapies and immunotherapies, in addition to standard therapies, for the treatment of oral cavity or oropharyngeal cancers. </p> </section> <section id="CD010341-sec-0003"> <h3 class="title" id="CD010341-sec-0003">Search methods</h3> <p>We searched the following electronic databases: Cochrane Oral Health Group Trials Register (to 3 February 2015), Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, 2015, Issue 1), MEDLINE via Ovid (1946 to 3 February 2015) and EMBASE via Ovid (1980 to 3 February 2015). We searched the US National Institutes of Health Trials Register (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), the World Health Organization Clinical Trials Registry Platform, the American Society of Clinical Oncology conference abstracts and the Radiation Therapy Oncology Group clinical trials protocols for ongoing trials. We placed no restrictions on the language or date of publication. </p> </section> <section id="CD010341-sec-0004"> <h3 class="title" id="CD010341-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials where more than 50% of participants had primary tumours of the oral cavity or oropharynx, and which compared targeted therapy or immunotherapy, plus standard therapy, with standard therapy alone. </p> </section> <section id="CD010341-sec-0005"> <h3 class="title" id="CD010341-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the results of the electronic searches, extracted data and assessed the risk of bias of the included studies. We attempted to contact study authors for missing data or clarification where necessary. We combined sufficiently similar studies in meta‐analyses using random‐effects models when there were at least four studies and fixed‐effect models when fewer than four studies. We obtained or calculated a hazard ratio (HR) and 95% confidence interval (CI) for the primary outcomes where possible. For dichotomous outcomes, we reported risk ratios (RR) and 95% CIs. </p> </section> <section id="CD010341-sec-0006"> <h3 class="title" id="CD010341-sec-0006">Main results</h3> <p>Twelve trials (2488 participants) satisfied the inclusion criteria. In the included trials, 12% of participants (298 participants) had tumours of the oral cavity and 59% (1468 participants) had oropharyngeal tumours. The remaining 29% had tumours of the larynx or hypopharynx and less than 1% had tumours at other sites. </p> <p>No included trial was at low risk of bias; seven had an unclear risk of bias, and five had a high risk of bias. We grouped trials by intervention type into three main comparisons: standard therapy plus epidermal growth factor receptor monoclonal antibody (EGFR mAb) therapy (follow‐up period 24 to 70 months); standard therapy plus tyrosine kinase inhibitors (TKIs) (follow‐up period 40 to 60 months) and standard therapy plus immunotherapy (follow‐up period 24 to 70 months), all versus standard therapy alone. </p> <p>Moderate quality evidence showed that EGFR mAb therapy may result in 18% fewer deaths when added to standard therapy (HR of mortality 0.82; 95% CI 0.69 to 0.97; 1421 participants, three studies, 67% oropharyngeal tumours, 2% oral cavity tumours). </p> <p>There was also moderate quality evidence that EGFR mAb may result in 32% fewer locoregional failures when added to radiotherapy (RT) (HR 0.68; 95% CI 0.52 to 0.89; 424 participants, one study, 60% oropharyngeal tumours). </p> <p>A subgroup analysis separating studies by type of standard therapy (radiotherapy (RT) or chemoradiotherapy (CRT)) showed some evidence that adding EGFR mAb therapy to RT may result in a 30% reduction in the number of people whose disease progresses (HR 0.70; 95% CI 0.54 to 0.91; 424 participants, one study, 60% oropharyngeal tumours, unclear risk of bias). For the subgroup comparing EGFR mAb plus CRT with CRT alone there was insufficient evidence to determine whether adding EGFR mAb therapy to CRT impacts on progression‐free survival (HR 1.08; 95% CI 0.89 to 1.32; 891 participants, one study, 70% oropharyngeal tumours, high risk of bias). The high subgroup heterogeneity meant that we were unable to pool these subgroups. </p> <p>There was evidence that adding cetuximab to standard therapy may result in increased skin toxicity and rash (RR 6.56; 95% CI 5.35 to 8.03; 1311 participants, two studies), but insufficient evidence to determine any difference in skin toxicity and rash in the case of nimotuzumab (RR 1.06; 95% CI 0.85 to 1.31; 92 participants, one study). </p> <p>There was insufficient evidence to determine whether TKIs added to standard therapy impacts on overall survival (HR 0.99; 95% CI 0.62 to 1.57; 271 participants, two studies; very low quality evidence), locoregional control (HR 0.89; 95% CI 0.53 to 1.49; 271 participants, two studies; very low quality evidence), disease‐free survival (HR 1.51; 95% CI 0.61 to 3.71; 60 participants, one study; very low quality evidence) or progression‐free survival (HR 0.80; 95% CI 0.51 to 1.28; 271 participants, two studies; very low quality evidence). We did find evidence of an increase in skin rash (erlotinib: RR 6.57; 95% CI 3.60 to 12.00; 191 participants, one study; lapatinib: RR 2.02; 95% CI 1.23 to 3.32; 67 participants, one study) and gastrointestinal complaints (lapatinib: RR 15.53; 95% CI 2.18 to 110.55; 67 participants, one study). </p> <p>We found very low quality evidence from one small trial that adding recombinant interleukin (rIL‐2) to surgery may increase overall survival (HR 0.52; 95% CI 0.31 to 0.87; 201 participants, 62% oral cavity tumours, 38% oropharyngeal tumours) and there was insufficient evidence to determine whether rIL‐2 impacts on adverse effects. </p> </section> <section id="CD010341-sec-0007"> <h3 class="title" id="CD010341-sec-0007">Authors' conclusions</h3> <p>We found some evidence that adding EGFR mAb to standard therapy may increase overall survival, progression‐free survival and locoregional control, while resulting in an increase in skin toxicity for some mAb (cetuximab). </p> <p>There is insufficient evidence to determine whether adding TKIs to standard therapies changes any of our primary outcomes. </p> <p>Very low quality evidence from a single study suggests that rIL‐2 combined with surgery may increase overall survival compared with surgery alone. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010341-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010341-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010341-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010341-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010341-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010341-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010341-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD010341-abs-0011">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010341-abs-0003" lang="en"> <h3>Treatments for cancers of the mouth and throat: therapies targeted at cancer cells and therapies to boost the body’s immune system </h3> <p><b>Review question</b> </p> <p>This review looks at the evidence for the benefits of new kinds of therapies for treating cancer of the mouth (oral cavity cancer) and cancer of the throat (oropharyngeal cancer) used together with standard treatments. One is the targeting of cancer cells directly whilst the other aims to boost the body’s own immune system to combat the cancer more effectively. Do these treatments result in differences in overall survival, cancer‐free survival, keeping the cancer limited to that area of the body, recurrence of the cancer, quality of life and harmful or unwanted effects? </p> <p><b>Background</b> </p> <p>Oral cancers (cancer of the mouth and cancer of the throat) are the sixth most common cancer worldwide, accounting for an estimated 4% of all cancers. There is a higher frequency of these cancers in men. Smoking, alcohol consumption and betel quid chewing are the main risk factors. Cancer of the throat is associated with infection from the human papilloma virus (HPV), which can be transmitted through sexual contact. Low socioeconomic status (a measure of a person's income, education and occupation in relation to other people's) is associated with a higher frequency of oral cancers and poorer survival rates. Survival following a diagnosis of mouth or throat cancer remains poor, with around 50% of people still alive at five years (five‐year survival rate). </p> <p>New therapies targeted at the cells that give rise to oral cancers are being developed. The advantage these may have over conventional chemotherapy is that rather than affecting both healthy and cancerous cells they just target cancer cells. </p> <p>Immunotherapy (also known as biological therapy, biotherapy or biological response modifier therapy) may improve the functioning of the immune system so it is more effective at destroying cancer cells. Local immunotherapy delivers treatment directly into the tumour and systemic immunotherapy targets the whole body, and may be useful for stopping the cancer spreading or the return of primary tumours in more advanced cancer. </p> <p><b>Study characteristics</b> </p> <p>The evidence in this review is up‐to‐date as of February 2015<b>.</b> We found 12 studies suitable for inclusion with a total of 2488 participants. Twelve per cent of participants (298) had tumours in the mouth and 59% (1468) had tumours in the throat. The remaining 29% of participants had tumours of the voice box or lower part of throat and less than 1% had tumours at other sites. We grouped trials by treatment into three main comparisons: standard therapy with or without epidermal growth factor receptor monoclonal antibody (EGFR mAb) therapy (which is a targeted therapy), standard therapy with or without tyrosine kinase inhibitors (TKIs) (which is a targeted therapy) and standard therapy with or without immunotherapy (which is an immune‐boosting therapy). </p> <p><b>Key results</b> </p> <p>We found that adding EGFR mAb, a targeted therapy, to standard therapy may increase overall survival, cancer‐free survival, keeping the cancer limited to that area of the body and may decrease recurrence of the cancer. However, it may result in an increase in skin problems for some. </p> <p>There is not enough evidence to know whether TKIs added to standard therapies results in a change in overall survival, cancer‐free survival, keeping the cancer limited to that area of the body or recurrence of the cancer. </p> <p>One study suggested that a type of immunotherapy, rIL‐2, combined with surgery, may increase overall survival. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the evidence available ranges from moderate quality (for EGFR mAb) to very low quality (for TKIs and rIL‐2), which limits our confidence in the reliability of our findings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010341-sec-0143" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010341-sec-0143"></div> <h3 class="title" id="CD010341-sec-0144">Implications for practice</h3> <section id="CD010341-sec-0144"> <p>Presently, surgery or radiotherapy (RT), or both, are the primary modalities used to treat early stage or resectable oral cavity cancers. In advanced stages of the disease, organ function preservation approaches (i.e. concurrent chemoradiotherapy (CRT) and sequential therapies) are preferred over surgery. Targeted therapies are being developed to complement conventional treatments, to increase effectiveness and reduce toxicity. </p> <p>There is some evidence from this review that administering monoclonal antibodies (mAb) against the epidermal growth factor receptor (EGFR) in combination with standard therapies can improve the outcomes in people with oral cavity and oropharyngeal cancers. Moderate quality evidence indicates that EGFR mAb concomitant with standard therapies increase overall survival and locoregional control when compared with standard therapy alone. It is promising that there is no evidence that side effects are significantly increased, with the exception of evidence of an increase in skin toxicity and rash in the case of cetuximab. </p> <p>While there is some suggestion from the progression‐free survival and overall survival data that adding mAb to RT may improve these outcomes whilst mAb to CRT may not, as yet we cannot be confident in this conclusion and much more evidence is required before any changes to clinical practice are made on this basis. </p> <p>As the remit of this review was to evaluate the efficacy of targeted therapies and immunotherapies, we have not compared particular treatment combinations where there are differences in the trial arms aside from the targeted and immunotherapies. However, in the update of this review, we plan to include trials comparing concomitant mAb and RT with concomitant CRT (CRT being the current evidence‐based standard of care), due to the clinical importance of this comparison in the light of our results. </p> <p>The role of recombinant interleukin (rIL‐2) in addition to the concurrent standard of care remains to be defined, as the very low quality evidence presented here was based on old, single trials. Future trials examining the role of immunotherapies through checkpoint inhibitors should help us shed more light on the role of immunotherapies in head and neck cancer. </p> <p>From the trials included in this systematic review, there is insufficient evidence of additional benefits of tyrosine kinase inhibitors (TKIs) administered concomitantly with standard therapies. </p> <p>There is no evidence to suggest a benefit of administering BCG‐CWP prior to surgery, compared with standard treatments alone, and currently there does not seem to be a role for the use of this treatment for oral and oropharyngeal cancers outside the research setting. </p> </section> <h3 class="title" id="CD010341-sec-0145">Implications for research</h3> <section id="CD010341-sec-0145"> <p>The evidence presented in this review was sparse and further research into the efficacy of targeted therapies is warranted. Several outcomes for different interventions have only been evaluated through single trials, and independent replication of these studies is needed. </p> <p>As none of the studies included in this study were at low risk of bias, and five were at high risk, this is a clear signal that standards of conduct and reporting in randomised controlled trials of targeted therapies could be improved. Three of the studies used a placebo control indicating that double blinding is indeed possible in targeted therapy trials to reduce the risk of bias for the more subjective outcomes such as adverse effects and quality of life (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). However, if the use of a placebo control is not deemed possible for practical or ethical reasons, adopting clear outcome criteria and using a panel of experts blinded to intervention to review outcomes would reduce the risk of detection bias for more subjective outcomes. </p> <p>Future trials will likely be stratified by human papilloma virus (HPV) status, and therefore future systematic reviews and meta‐analyses will need to take account of HPV status. </p> <p>Future trials should investigate the optimal time to administer the targeted therapies and determine whether they are more effective as neoadjuvant treatments, when given with standard therapies, or at maintenance doses following standard therapies. </p> <p>In addition, we identified multiple ongoing studies when screening studies for this review, comparing concomitant mAb (to EGFR) and RT with standard concomitant CRT. The results from these trials will provide further evidence of the relative benefits and toxicities of these two treatments. </p> <p>The mAb studies that we were able to include in this review all assessed mAb against EGFR. Further high quality trials are required to evaluate mAb against other targets such as vascular endothelial growth factor (VEGF) and tyrosine kinases. </p> <p>Previous research focusing on cytokine immunotherapy has been limited. Future research on checkpoint inhibitions using mAb may provide more insight into the value of immunotherapy for treating these cancers. </p> <p>Further research identifying biomarkers that are predictive of a tumour's response to molecularly targeted agents is essential, in order to identify people who are likely to benefit from treatment with these agents. Accurately selecting participants who may benefit from a specific targeted therapy could spare other people from the additional toxicities of unsuccessful therapies. </p> <p>Standard treatments, such as CRT or surgery, are associated with substantial toxicities and the addition of targeted therapies may amplify these adverse effects. Therefore, future studies should report detailed and standardised safety/toxicity data, especially comparisons of toxicity between molecular targeted therapy combined with standard treatments versus standard treatments alone. Lastly, there are limited data available on outcome measures such as quality of life, cost and participants' preferences with targeted therapies. Only one study included in this review comprehensively assessed quality of life, and future research that measures these important outcomes is desirable. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010341-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010341-sec-0022"></div> <div class="table" id="CD010341-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity or oropharyngeal cancers</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br/> <b>Settings:</b> secondary care<br/> <b>Intervention:</b> EGFR mAb (either cetuximab or nimotuzumab + either RT or CRT) </p> <p><b>Comparison:</b> RT or CRT alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> <p><b> mAb</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.82</b> <br/> (0.69 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1421<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was an 18% reduction in death (during the follow‐up period) in the participants treated with EGFR mAb therapies in addition to standard therapies </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000 (113 to 156)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>347 per 1000 (301 to 396)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>577 per 1000 (515 to 639)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Locoregional control</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.68</b> <br/> (0.52 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>424<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was a 32% reduction in recurrence of cancer (during the follow‐up period) in the participants treated with EGFR mAb therapies (cetuximab) in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>112 per 1000 (87 to 144)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>297 per 1000 (237 to 370)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>510 per 1000 (421 to 607)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>We formed 2 subgroups: mAb therapy + RT versus RT alone and mAb therapy + CRT versus CRT alone. There was a significant difference between these subgroups (P value = 0.008; I<sup>2</sup> = 86%) and as a result we were unable to pool the data. The subgroup comparing mAb therapy + RT versus RT alone reported a 30% reduction in the number of people whose disease progresses if treated with EGFR mAb in addition to RT (HR 0.70; 95% CI 0.54 to 0.91; P value = 0.006). However, the subgroup comparing mAb therapy + CRT versus CRT alone reported no evidence of a difference in progression‐free survival (HR 1.08; 95% CI 0.89 to 1.32; P value = 0.76) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>A subgroup estimate shows evidence of an increase in skin toxicity/acneiform rash (all grades of adverse effects: RR 6.56, 95% CI 5.35 to 8.03; 1311 participants, 2 studies; adverse effects grades ≥ 3: RR 17.72, 95% CI 8.33 to 37.73; 1403 participants, 3 studies) in people treated with cetuximab in addition to standard therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>EGFR:</b> epidermal growth factor receptor; <b>mAb:</b> monoclonal antibody; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5‐year survival data (<a href="./references#CD010341-bbs2-0127" title="PulteD , BrennerH . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist2010;15(9):994‐1001. ">Pulte 2010</a>). </p> <p><sup>1</sup> Downgraded once for reporting bias (potential publication bias and poor reporting of EGFR and biopsy data in one study).<br/> <sup>2</sup> Downgraded once due to this being a single study at unclear risk of performance bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010341-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tyrosine kinase inhibitors plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tyrosine kinase inhibitors in addition to standard treatments for people with oral cavity and oropharyngeal cancers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br/> <b>Settings:</b> secondary care<br/> <b>Intervention:</b> tyrosine kinase inhibitors (erlotinib, gefitinib or lapatinib) + standard therapy (either RT or CRT) </p> <p><b>Comparison:</b> standard therapy (either RT or CRT alone) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> <p><b> Tyrosine kinase inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.99</b> <br/> (0.62 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in participant survival in people treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>159 per 1000 (102 to 239)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>402 per 1000 (275 to 557)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>646 per 1000 (478 to 808)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Locoregional control</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.89</b> <br/> (0.53 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in locoregional control in people treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>144 per 1000 (88 to 229)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>370 per 1000 (241 to 539)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>607 per 1000 (429 to 791)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Disease‐free Survival</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 1.51</b> <br/> (0.61 to 3.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in the length of time that participants survived without signs or symptoms of oral cavity cancer when treated with tyrosine kinase inhibitors (gefitinib) in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>231 per 1000 (101 to 476)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>543 per 1000 (271 to 854)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>795 per 1000 (473 to 980)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Progression‐free Survival</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.8</b> <br/> (0.51 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in the length of time that participants stayed alive with stable disease when treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>130 per 1000 (85 to 200)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>340 per 1000 (233 to 486)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>568 per 1000 (415 to 739)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>A subgroup estimate showed evidence of an increase in gastrointestinal complaints (all grades of adverse effects: RR 15.53, 95% CI 2.18 to 110.55; 67 participants, 1 study) in people treated with lapatinib in addition to standard therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5‐year survival data (<a href="./references#CD010341-bbs2-0127" title="PulteD , BrennerH . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist2010;15(9):994‐1001. ">Pulte 2010</a>). </p> <p><sup>1</sup> Downgraded once due reporting bias (data from a large study (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>) was not available). </p> <p><sup>2</sup> Downgraded once due to imprecision </p> <p><sup>3</sup> Downgraded once due to unclear risk of bias across multiple domains. </p> <p><sup>4</sup> Downgraded once for applicability ‐ only participants receiving RT as a standard therapy were included in this subgroup (no CRT). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010341-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Immunotherapy plus standard therapy versus standard therapy alone for the treatment of people with oral and oropharyngeal cancers</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Recombinant Interleukin (rIL‐2) in addition to surgery for the treatment of people with oral and oropharyngeal cancers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br/> <b>Settings:</b> secondary care<br/> <b>Intervention:</b> recombinant Interleukin (rIL‐2) + standard therapy (surgery) </p> <p><b>Comparison:</b> standard therapy (surgery) alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> <p><b> rIL‐2</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.52</b> </p> <p>(0.31 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>201<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was an 48% reduction in death in the groups treated with rIL‐2 in addition to standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1000<br/> (53 to 141) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>237 per 1000</p> <p>(149 to 363)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>421 per 1000</p> <p>(278 to 599)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Disease‐free survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.66</b> <br/> (0.43 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>201<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There is no evidence of a difference in the length of time that participants survived without signs or symptoms of cancer when treated with rIL‐2 in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>109 per 1000</p> <p>(72 to 163)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>290 per 1000</p> <p>(200 to 411)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> <p>(363 to 657)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>There was no evidence of an increase or reduction of nausea/vomiting, stomatitis or leukopenia in participants treated with rIL‐2 in addition to standard therapy (1 study, 30 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5‐year survival data (<a href="./references#CD010341-bbs2-0127" title="PulteD , BrennerH . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist2010;15(9):994‐1001. ">Pulte 2010</a>) </p> <p><sup>1</sup> Downgraded twice due to high/unclear risk of bias across domains.<br/> <sup>2</sup> Downgraded once due to this being a single study and due to applicability (only participants receiving surgery as a standard therapy were included in this subgroup (no RT/CRT). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010341-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010341-sec-0023"></div> <section id="CD010341-sec-0024"> <h3 class="title" id="CD010341-sec-0024">Description of the condition</h3> <p>Oral cancers are the sixth most common cancer worldwide, accounting for about 4% of all cancers, with an estimated 274,000 new cases of oral cavity and 130,000 new cases of oropharyngeal cancer worldwide in 2002 (<a href="./references#CD010341-bbs2-0113" title="JemalA , BrayF , Center MM, FerlayJ , WardE , FormanD . Global cancer statistics. CA: A Cancer Journal for Clinicians2011;61(2):69‐90. ">Jemal 2011</a>; <a href="./references#CD010341-bbs2-0123" title="ParkinDM , BrayF , FerlayJ , PisaniP . Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians2005;55(2):74‐108. ">Parkin 2005</a>; <a href="./references#CD010341-bbs2-0133" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4‐5):309‐16. ">Warnakulasuriya 2009</a>). The incidence of and mortality from oral cancers varies geographically; the highest age standardised rates of oral cancers are reported in parts of Europe (France, Hungary), Botswana and South Central Asia (Sri Lanka, Pakistan, Bangladesh and India) (<a href="./references#CD010341-bbs2-0123" title="ParkinDM , BrayF , FerlayJ , PisaniP . Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians2005;55(2):74‐108. ">Parkin 2005</a>). There is overwhelming evidence that tobacco use, alcohol consumption and betel quid chewing are the main risk factors in the aetiology of intraoral cancer (<a href="./references#CD010341-bbs2-0115" title="LaVecchiaC , TavaniA , FranceschiS , LeviF , CorraoG , NegriE . Epidemiology and prevention of oral cancer. Oral Oncology1997;33(5):302‐12. ">La Vecchia 1997</a>; <a href="./references#CD010341-bbs2-0117" title="MacfarlaneGJ , ZhengT , MarshallJR , BoffettaP , NiuS , BrasureJ , et al. Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case‐control studies. European Journal of Cancer. Part B, Oral Oncology1995;31B(3):181‐7. ">Macfarlane 1995</a>). There is also strong evidence that low socioeconomic status is associated with a higher incidence and poorer survival of oral cancers (<a href="./references#CD010341-bbs2-0097" title="FaggianoF , PartanenT , KogevinasM , BoffettaP . Socioeconomic differences in cancer incidence and mortality. In: KogevinasM , PearceN , SusserM , BoffettaP editor(s). Social Inequalities and Cancer. Lyon: IARC Scientific Publications No 138. International Agency for Research in Cancer, 1997. ">Faggiano 1997</a>). There is a higher incidence of oral cancers in men (<a href="./references#CD010341-bbs2-0100" title="FreedmanND , AbnetCC , LeitzmannMF , HollenbeckAR , SchatzkinA . Prospective investigation of the cigarette smoking‐head and neck cancer association by sex. Cancer2007; Vol. 110, issue 7:1593‐601. ">Freedman 2007</a>), which is generally attributed to a greater exposure to the known risk factors and the vast majority of cases occur in men over 50 years of age (<a href="./references#CD010341-bbs2-0133" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4‐5):309‐16. ">Warnakulasuriya 2009</a>) and among low socioeconomic groups (<a href="./references#CD010341-bbs2-0088" title="ConwayDI , PetticrewM , MarlboroughH , BerthillerJ , HashibeM , MacphersonLM . Socioeconomic inequalities and oral cancer risk: a systematic review and meta‐analysis of case‐control studies. International Journal of Cancer2008;122(12):2811‐9. ">Conway 2008</a>). However, the ratio of males to females diagnosed with oral cancers has declined from approximately 5:1 in the 1960s to less than 2:1 in 2002 (<a href="./references#CD010341-bbs2-0123" title="ParkinDM , BrayF , FerlayJ , PisaniP . Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians2005;55(2):74‐108. ">Parkin 2005</a>). Another trend is the increasing incidence of oral cavity and oropharyngeal cancers in younger adults in the European Union and the US (<a href="./references#CD010341-bbs2-0133" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4‐5):309‐16. ">Warnakulasuriya 2009</a>). </p> <p>The epidemiological data concerning 'oral cancer' obscures the fact that 'oral cancer' includes both oral cavity (OC) and oropharyngeal (OP) cancers, which have clinically different aetiologies, are generally diagnosed at different stages and are managed in different ways. People with OC cancers more commonly present with early stage disease when compared with people with OP cancers. Most people with resectable OC cancers are treated with surgery, with or without adjuvant radiotherapy (RT) or chemoradiotherapy (CRT). It is now recognised that oral infection with human papilloma virus (HPV) is strongly associated with the development of OP cancer. HPV infection is thought to be associated with the increased incidence of OP cancer, which may be linked to an increase in sexual activity (<a href="./references#CD010341-bbs2-0092" title="D'SouzaG , KreimerAR , ViscidiR , PawlitaM , FakhryC , KochWM , et al. Case‐control study of human papillomavirus and oropharyngeal cancer. New England Journal of Medicine2007; Vol. 356, issue 19:1944‐56. ">D'Souza 2007</a> ; <a href="./references#CD010341-bbs2-0108" title="HammarstedtL , LindquistD , DahlstrandH , RomanitanM , DahlgrenLO , JonebergJ , et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. International Journal of Cancer2006;119(11):2620‐3. ">Hammarstedt 2006</a>). The link between oncogenic HPV and OP cancer is strong and has been documented in numerous studies, fulfilling the epidemiological criteria for disease causality, especially in the development of OP cancer in non‐smokers (<a href="./references#CD010341-bbs2-0132" title="SturgisEM , CinciripiniPM . Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus‐associated cancers?. Cancer2007;110(7):1429‐35. ">Sturgis 2007</a>). The proportion of people with OP cancer who are HPV positive has increased dramatically (<a href="./references#CD010341-bbs2-0083" title="AttnerP , DuJ , NasmanA , HammarstedtL , RamqvistT , LindholmJ , et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. International Journal of Cancer2010;126(12):2879‐84. ">Attner 2010</a>; <a href="./references#CD010341-bbs2-0130" title="RyersonAB , PetersES , CoughlinSS , ChenVW , GillisonML , ReichmanME , et al. Burden of potentially human papillomavirus‐associated cancers of the oropharynx and oral cavity in the US, 1998‐2003. Cancer2008;113(10 Suppl):2901‐9. ">Ryerson 2008</a>), but it is interesting to note that this group of people have significantly improved rates of both overall survival and disease‐free survival (<a href="./references#CD010341-bbs2-0098" title="FakhryC , GillisonML . Clinical implications of human papillomavirus in head and neck cancers. Journal of Clinical Oncology2006;24(17):2606‐11. ">Fakhry 2006</a>; <a href="./references#CD010341-bbs2-0099" title="FakhryC , WestraWH , LiS , CmelakA , RidgeJA , PintoH , et al. Improved survival of patients with human papillomavirus‐positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute2008; Vol. 100, issue 4:261‐9. ">Fakhry 2008</a>; <a href="./references#CD010341-bbs2-0116" title="LicitraL , PerroneF , BossiP , SuardiS , MarianiL , ArtusiR , et al. High‐risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology2006;24(36):5630‐6. ">Licitra 2006</a>). In comparison, the level of evidence and the degree of association between OC cancer and HPV is much weaker (<a href="./references#CD010341-bbs2-0109" title="HerreroR , CastellsagueX , PawlitaM , LissowskaJ , KeeF , BalaramP , et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. Journal of the National Cancer Institute2003;95(23):1772‐83. ">Herrero 2003</a>). </p> <p>The most common cancer of the OC and oropharynx is the squamous cell carcinoma that arises from the lining of the OC; over 95% of all OC cancers are squamous cell carcinomas. Despite significant technical advances in the treatment of oral cancer, it still has a significant mortality with 128,000 deaths recorded in 2000, representing nearly half of the incident cases (48%) (<a href="./references#CD010341-bbs2-0122" title="ParkinD . Global cancer statistics in the year 2000. Lancet Oncology2001;2(9):533‐43. ">Parkin 2001</a>). Survival following a diagnosis of OC or OP cancer remains poor with five‐year survival around 50% overall globally, with only limited improvement since the late 1970s (<a href="./references#CD010341-bbs2-0133" title="WarnakulasuriyaS . Global epidemiology of oral and oropharyngeal cancer. Oral Oncology2009;45(4‐5):309‐16. ">Warnakulasuriya 2009</a>). In the US, the five‐year survival rates were 63.2% (2005 to 2011) and death rates did not changed significantly between 2002 and 2012 (<a href="./references#CD010341-bbs2-0120" title="National Cancer Institute ‐ Surveillance, Epidemiology , and End Results Program. SEER Stat fact sheets: oral cavity and pharynx cancer. seer.cancer.gov/statfacts/html/oralcav.html (accessed 23 September 2015). ">National Cancer Institute 2015</a>). </p> </section> <section id="CD010341-sec-0025"> <h3 class="title" id="CD010341-sec-0025">Description of the intervention</h3> <p>With increasing understanding of the molecular changes associated with carcinogenesis of head and neck cancer, new targeted therapies are being developed to overcome those molecular changes. These changes may be associated with autonomous proliferation, dysregulation of growth inhibitory signals, evasion of apoptosis, development of immortalisation, tumour‐induced angiogenesis, and tissue invasion and metastasis. Targeted therapies against any of these changes may represent therapeutic opportunities. When compared with conventional cytotoxic chemotherapies, which are relatively unselective, acting against both cancer cells and normal cells, targeted therapies are more selective against cancer cells and, therefore, have the potential to minimise toxicities while maximising therapeutic outcomes. For example, epidermal growth factor receptors (EGFR) are found to be over‐expressed in 80% to 90% of head and neck cancers (<a href="./references#CD010341-bbs2-0106" title="GrandisJ , TweardyD . Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research1993;53(15):3579‐84. ">Grandis 1993</a>), and EGFR over‐expression is associated with reduced survival (<a href="./references#CD010341-bbs2-0081" title="AngKK , BerkeyBA , TuX , ZhangHZ , KatzR , HammondEH , et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research2002;62(24):7350‐6. ">Ang 2002</a>; <a href="./references#CD010341-bbs2-0093" title="DemiralAN , SariogluS , BirlikB , SenM , KinayM . Prognostic significance of EGF receptor expression in early glottic cancer. Auris, Nasus, Larynx2004;31(4):417‐24. ">Demiral 2004</a>; <a href="./references#CD010341-bbs2-0118" title="MauriziM , AlmadoriG , FerrandinaG , DistefanoM , RomaniniME , CadoniG , et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. British Journal of Cancer1996;74(8):1253‐7. ">Maurizi 1996</a>), therefore making EGFR a rational target for the treatment of head and neck cancer. </p> <p>Monoclonal antibodies (mAb) have been developed that target EGFR, but there is a range of other targets including vascular endothelial growth factor (VEGF), and a group of proteins known as tyrosine kinases. As well as tyrosine kinase inhibitors, which have multiple targets, research has identified a wide range of specific targets. There is a large group of small molecular multiple kinase inhibitors, some of which inhibit multiple targets (e.g. sorafenib, sunitinib, lapatinib) and others that have a range of specific targets. Specific targets include PARP (poly (ADP‐ribose) polymerase) inhibitors (e.g. iniparib and olaparib), proteasome inhibitors (e.g. bortezomib), histone acetylation inhibitors (e.g. vorinostat and romidepsin), mTOR (mammalian target of rapamycin) inhibitors (e.g. everolimus and temsirolimus), COX (cyclo‐oxygenase) inhibitors (e.g. celecoxib), CDK (cyclin‐dependant kinase) inhibitors (e.g. seliciclib and flavopiridol) and a heat shock protein inhibitor (e.g. tanespimycin). </p> <p>In addition, it is thought that cancer may develop following suboptimal functioning or a breakdown of the immune system. Immunotherapy (also known as biological therapy, biotherapy or biological response modifier therapy) may repair, stimulate or enhance the function of the immune system in destroying the cancer cells (<a href="./references#CD010341-bbs2-0090" title="Cancer Research UK (CRUK). Learn about cancer: immunotherapy. info.cancerresearchuk.org/cancerandresearch/all‐about‐cancer/what‐is‐cancer/treating‐cancer/history‐of‐immunotherapy/(accessed January 2012). ">CRUK 2012</a>). Local immunotherapy delivers treatment directly into the tumour and systemic immunotherapy targets the whole body and may be useful for stopping metastasis or the recurrence of primary tumours in more advanced cancer. Non‐specific immunotherapy is designed to boost the capability of the immune system cells, such as T‐cells, NK‐cells and macrophages to fight against any foreign cells (<a href="./references#CD010341-bbs2-0091" title="Cancer Treatment Centers of America (CTCA). Biotherapy/immunotherapy for oral cancer. www.cancercenter.com/oral‐cancer/biotherapy‐immunotherapy.cfm (accessed 18 January 2012). ">CTCA 2012</a>). </p> <p>Based on mechanisms of action, immunotherapy can be broadly divided into different categories such as vaccine‐based immunotherapy (peptide vaccine versus cell‐based vaccine), adoptive cell transfer immunotherapy, checkpoint inhibition‐based immunotherapy (e.g. CTLA‐4 inhibitors, PD‐1 inhibitors, PD‐L1 inhibitors, etc.) and other approaches (e.g. biological response modifiers and positive co‐stimulatory molecules modulation) (<a href="./references#CD010341-bbs2-0096" title="DrakeCG , LipsonEJ , BrahmerJR . Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology2014;11(1):24‐37. ">Drake 2014</a>; <a href="./references#CD010341-bbs2-0121" title="PardollDM . The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer2012;12:252‐64. ">Pardoll 2012</a>; <a href="./references#CD010341-bbs2-0129" title="RosenbergSA . Decade in review ‐ cancer immunotherapy. Entering the mainstream of cancer treatment. Nature Reviews Clinical Oncology2014;11:630‐2. ">Rosenberg 2014</a>). In particular, checkpoint inhibition‐based immunotherapy approaches have shown promise in multiple cancers, including melanoma (<a href="./references#CD010341-bbs2-0126" title="PostowMA , ChesneyJ , PavlickAC , RobertC , GrossmannK , McDermottD , et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine2015;372:2006‐17. ">Postow 2015</a>; <a href="./references#CD010341-bbs2-0128" title="RobertC , SchachterJ , LongGV , AranceA , GrobJJ , MortierL , et al. Pemborlizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine2015;372:2521‐32. ">Robert 2015</a>), and non‐small cell lung cancer (<a href="./references#CD010341-bbs2-0087" title="BrahmerJ , ReckampKL , BaasP , CrinòL , EberhardtWE , PoddubskayaE . Nivolumab versus docetaxel in advanced squamous‐cell non‐small‐cell lung cancer. New England Journal Medicine2015;373:123‐35. ">Brahmer 2015</a>). </p> <p>Oncolytic adenoviruses have been developed that replicate preferentially in tumours (<a href="./references#CD010341-bbs2-0089" title="CromptonAM , KirnDH . From ONYX‐015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Current Cancer Drug Targets2007;7(2):133‐9. ">Crompton 2007</a>; <a href="./references#CD010341-bbs2-0136" title="YuW , FangH . Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets2007;7(2):141‐8. ">Yu 2007</a>), resulting in the destruction of tumour cells. An example is oncolytic herpes simplex virus such as HF10 (<a href="./references#CD010341-bbs2-0101" title="FujimotoY , MizunoT , SugiuraS , GoshimaF , KohnoS , NakashimaT , et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Oto‐Laryngologica2006;126(10):1115‐7. ">Fujimoto 2006</a>), also being developed to target head and neck cancer cases. The efficacy of the delivery methods of these oncolytic adenoviruses (e.g. intratumoural approach versus intravenous delivery) is also under evaluation (<a href="./references#CD010341-bbs2-0094" title="DengH , SambrookPJ , LoganRM . The treatment of oral cancer: an overview for dental professionals. Australian Dental Journal2011;56(3):244‐52, 341. ">Deng 2011</a>). Antibody directed pro‐drug therapy (ADEPT) can be used to attach an enzyme to the cancer cells that converts a pro‐drug to an active anti‐cancer agent at the site of the tumour (<a href="./references#CD010341-bbs2-0090" title="Cancer Research UK (CRUK). Learn about cancer: immunotherapy. info.cancerresearchuk.org/cancerandresearch/all‐about‐cancer/what‐is‐cancer/treating‐cancer/history‐of‐immunotherapy/(accessed January 2012). ">CRUK 2012</a>). </p> <p>There is a great deal of pre‐clinical research in the area of targeted biological therapies for cancer, which is being conducted in laboratories all over the world. </p> </section> <section id="CD010341-sec-0026"> <h3 class="title" id="CD010341-sec-0026">How the intervention might work</h3> <p>The observation that epidermal growth factor is over‐expressed in malignant head and neck squamous cell carcinomas, and that high levels of EGFRs are correlated with poor prognosis and poor response to RT has led to EGFR being recognised as an important therapeutic target in cancer (<a href="./references#CD010341-bbs2-0084" title="BernardesVF , Gleber‐NettoFO , SousaSF , SilvaTA , AguiarMC . Clinical significance of EGFR, Her‐2 and EGF in oral squamous cell carcinoma: a case control study. Journal of Experimental and Clinical Cancer Research2010; Vol. 29:40. ">Bernardes 2010</a>). </p> <p>mAb against EGFR, such as cetuximab, panitumub, nimotuzumab and palutumumab, have been developed for head and neck cancers (<a href="./references#CD010341-bbs2-0114" title="KunduSK , NestorM . Targeted therapy in head and neck cancer. Tumour Biology2012;33(3):707‐21. ">Kundu 2012</a>). They work by binding to the extracellular domain of EGFR and prevent dimerisation, internalisation and autophosphorylation. EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, work by binding to the intracellular tyrosine kinase domain of EGFR to prevent intracellular signal transduction. EGFR inhibitors have also been shown to enhance tumour radiosensitivity (<a href="./references#CD010341-bbs2-0107" title="HamakawaH , NakashiroK , SumidaT , ShintaniS , MyersJN , TakesRP , et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head &amp; Neck2008;30(6):800‐9. ">Hamakawa 2008</a>). This provides biological rationale to examine the effectiveness of combining EGFR therapy with RT. </p> <p>Other targeted therapies include VEGF receptor inhibitors (e.g. bevacizumab and vandetanib), which inhibit the formation of new blood vessels that supply the tumour. </p> <p>Efforts have also focused on the resistance mechanism of targeted therapies such as initial molecular response and adaptation that may occur in tumour cells early upon exposure to a targeted agent (<a href="./references#CD010341-bbs2-0125" title="PazarentzosE , BivonaTG . Adaptive stress signaling in targeted cancer therapy resistance. Oncogene2015; Vol. 34, issue 45:5599‐606. [DOI: 10.1038/onc.2015.26] ">Pazarentzos 2015</a>). </p> <p>Cancer immunotherapy works by enabling parts of the immune system to attack cancer cells. For example, vaccine‐based immunotherapy focuses on raising specific T‐cell or B‐cell response against cancer. Adoptive cell transfer immunotherapy aims to use cells such as tumour infiltrating lymphocytes to enhance T‐cell response against cancer. As most cancer cells have developed mechanisms to evade immune‐mediated attack, such as the expression of molecules (known as immune checkpoints) that modulate T‐cell proliferative and killing, checkpoint inhibition‐based immunotherapy aims to overcome these immune checkpoints. Common approaches to overcome immune checkpoints include inhibitions of CTLA‐4, PD‐1 and PD‐L1 to enhance the immune system's ability to recognise and attack cancer cells. </p> <p>Immunotoxins (toxins bound to antibodies or growth factors) and antisense strategies (where drugs are designed to bind to the messenger ribonucleic acid (mRNA) of a target protein, inhibiting the production of that protein) are further areas of research for effective cancer treatments (<a href="./references#CD010341-bbs2-0082" title="Antisense Therapeutics Limited(ATL) . Genes proteins and the drug discovery process. www.antisense.com.au/_108.asp (accessed 18 January 2012). ">ATL 2012</a>; <a href="./references#CD010341-bbs2-0114" title="KunduSK , NestorM . Targeted therapy in head and neck cancer. Tumour Biology2012;33(3):707‐21. ">Kundu 2012</a>). Immunotoxins (also known as immunoconjugates) consist of three components: an antibody that binds to the cancer cells strongly and specifically, an effector molecule that has a high ability to kill cancer cells and a linker to ensure that the effector molecule does not get disconnected from the antibody prior to delivery to the cancer cells. This helps to optimise the therapeutic index of the effector molecule and minimise the systemic side‐effects (<a href="./references#CD010341-bbs2-0131" title="SmagloBG , AldeghaitherD , WeinerLM . The development of immunoconjugates for targeted cancer therapy. Nature Reviews Clinical Oncology2014;11:637‐48. ">Smaglo 2014</a>). </p> <p>It has also been observed that specific genetic mutations, some of which are inherited and some of which occur during the lifetime, are associated with the subsequent development of specific cancers. Mutations can produce oncogenes that result in rapid cell division or alternatively 'switch‐off' tumour suppressor genes, which would normally repair deoxyribonucleic acid (DNA) mistakes and slow down cell division (<a href="./references#CD010341-bbs2-0094" title="DengH , SambrookPJ , LoganRM . The treatment of oral cancer: an overview for dental professionals. Australian Dental Journal2011;56(3):244‐52, 341. ">Deng 2011</a>). Gene therapies are designed to 'correct' the mutations, and have been used in early trials but are far from being optimised for clinical use (<a href="./references#CD010341-bbs2-0135" title="XiS , GrandisJR . Gene therapy for the treatment of oral squamous cell carcinoma. Journal of Dental Research2003;82(1):11‐6. ">Xi 2003</a>). </p> <p>Some non‐specific immunotherapy treatments such as interferon and colony stimulating factors are already used to treat cancer in conjunction with other modalities such as radiation and chemotherapy. </p> </section> <section id="CD010341-sec-0027"> <h3 class="title" id="CD010341-sec-0027">Why it is important to do this review</h3> <p>The Cochrane Oral Health Group undertook an extensive prioritisation exercise in 2014 to identify a core portfolio of the most clinically important titles to maintain on <i>The Cochrane Library</i>. The oral/maxillofacial surgery expert panel identified this review as a clinically important priority title. </p> <p>This review is the fourth in a series of Cochrane reviews looking at different treatment modalities for OC and OP cancers: surgical treatment (<a href="./references#CD010341-bbs2-0085" title="BessellA , GlennyAM , FurnessS , ClarksonJE , OliverR , ConwayDI , et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD006205.pub3] ">Bessell 2011</a>), chemotherapy (<a href="./references#CD010341-bbs2-0102" title="FurnessS , GlennyAM , WorthingtonHV , PavittS , OliverR , ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD006386.pub3] ">Furness 2011</a>), and RT (<a href="./references#CD010341-bbs2-0103" title="GlennyAM , FurnessS , WorthingtonHV , ConwayDI , OliverR , ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD006387.pub2] ">Glenny 2010</a>). There is a great deal of current research into new therapies for cancer and many of these make the headlines in the news. However, there is a significant time lag between laboratory discoveries and the introduction of new treatments into clinical care. This review will evaluate the randomised controlled trials of targeted and immunological therapies for people with OC or OP cancers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010341-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010341-sec-0028"></div> <p>To assess the effects of molecularly targeted therapies and immunotherapies, in addition to standard therapies, for the treatment of oral cavity or oropharyngeal cancers. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010341-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010341-sec-0029"></div> <section id="CD010341-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010341-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials that evaluated targeted therapy or immunotherapy, plus standard therapy (chemotherapy, RT, surgery or a combination of these), compared with the standard therapy alone. Studies had to have a minimum follow‐up period of six months. </p> <p>We intended to also include trials comparing targeted therapy or immunotherapy alone with placebo, or standard therapy plus targeted therapy with standard therapy plus immunotherapy, but we did not identify any trials of these types that met our inclusion criteria. </p> </section> <section id="CD010341-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included people diagnosed with cancer of either the OC or the oropharynx as defined by the International Classification of Diseases for Oncology (ICD‐O) codes as C01‐C02, C03, C04, C05‐C06 (OC cancers) or cancer of the oropharynx (ICD‐O: C09, C10). We excluded trials where participants only had cancers of hypopharynx (ICD‐O: C13), nasopharynx (ICD‐O: C11), larynx (ICD‐O: C32) and lip (ICD‐O: C00), or metastatic disease (<a href="./references#CD010341-bbs2-0134" title="World Health Organization (WHO). ICD‐O. International Statistical Classification of Diseases and Related Health pProblems, 1989 Revision. Geneva: World Health Organization, 1992. ">WHO 1992</a>) (<a href="#CD010341-tbl-0004">Table 1</a>). </p> <div class="table" id="CD010341-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of inclusion and exclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Inclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exclusion criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Location of cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with primary cancer of the oral cavity (ICD‐O: C01‐06) or oropharynx (ICD‐O: C09‐10 ‐ includes tonsil)<br/> People with primary cancer of the head and neck where &gt; 50% of cases had oral/oropharynx cancer. If separate oral/oropharynx data are available they will be used to the exclusion of the combined head and neck cancer data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lip (ICD‐O: C00) cancers</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parotid gland (ICD‐O: C07), unspecified major salivary gland (ICD‐O: C08)<br/> and thyroid gland (ICD‐O: C73.9) cancers<br/> Nasopharynx (ICD‐O: C11), hypopharynx (ICD‐O: C13), larynx (ICD‐O: C32), pyriform sinus (ICD‐O: C12.9), accessory sinuses (ICD‐O: C31), nasal cavity and middle ear (ICD‐O: C30) cancers<br/> In combined head and neck trials, these cancers will be included if they comprise &lt; 50% of the total cancer diagnoses of participants </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ICD‐O: International Classification of Diseases for Oncology.</p> </div> </div> <p>We included trials where participants were described as having head and neck cancer if data were available separately for those participants who had cancer of the OC or oropharynx, or at least 50% of participants in the trial had OC or OP cancers. We included primary squamous cell carcinomas, histological variants of squamous cell carcinomas (adenosquamous, verrucous, basaloid, papillary) and carcinoma in situ. </p> <p>We excluded epithelial malignancies of the salivary glands, odontogenic tumours, all sarcomas and lymphomas as these have a different aetiology and are managed differently. </p> </section> <section id="CD010341-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Targeted therapy or immunotherapy of the primary tumour had to be one of the primary interventions, and had to be administered concomitantly with standard therapy. We considered any mode of administration of targeted therapy or immunotherapy. We excluded any trials where participants had received any prior intervention other than diagnostic intervention. </p> </section> <section id="CD010341-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010341-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010341-list-0001"> <li> <p>Overall survival/total mortality (and disease‐related mortality if possible).</p> </li> <li> <p>Locoregional control.</p> </li> <li> <p>Disease‐free survival (DFS).</p> </li> <li> <p>Progression‐free survival (PFS) or time to recurrence.</p> </li> </ul> </p> </section> <section id="CD010341-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010341-list-0002"> <li> <p>Harms associated with treatment (adverse events).</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Direct and indirect costs to participants and health services.</p> </li> <li> <p>Participant satisfaction.</p> </li> </ul> </p> </section> </section> </section> <section id="CD010341-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>To identify studies for this review, we developed detailed search strategies for each database searched. We based these on the search strategy developed for MEDLINE (Ovid) but revised appropriately for each database. The search strategy used a combination of controlled vocabulary and free‐text terms and was linked with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity‐maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (updated March 2011) (<a href="./references#CD010341-bbs2-0111" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)<i>.</i> Details of the MEDLINE search are provided in <a href="./appendices#CD010341-sec-0149">Appendix 1</a>. The search of EMBASE was linked to the Cochrane Oral Health Group filter for identifying RCTs. </p> <section id="CD010341-sec-0038"> <h4 class="title">Language</h4> <p>We did not place any restrictions on language or date of publication when searching the electronic databases. Any non‐English papers identified were translated and assessed for eligibility. </p> </section> <section id="CD010341-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD010341-list-0003"> <li> <p>Cochrane Oral Health Group's Trials Register (to 3 February 2015) (<a href="./appendices#CD010341-sec-0150">Appendix 2</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, 2015, Issue 2) (<a href="./appendices#CD010341-sec-0151">Appendix 3</a>); </p> </li> <li> <p>MEDLINE via Ovid (1946 to 3 February 2015) (<a href="./appendices#CD010341-sec-0149">Appendix 1</a>); </p> </li> <li> <p>EMBASE via Ovid (1980 to 3 February 2015) (<a href="./appendices#CD010341-sec-0152">Appendix 4</a>). </p> </li> </ul> </p> </section> <section id="CD010341-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We searched the following databases for ongoing trials:</p> <p> <ul id="CD010341-list-0004"> <li> <p>US National Institutes of Health Trials Register (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) (to 3 February 2015); </p> </li> <li> <p>World Health Organization (WHO) Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/default.aspx" target="_blank">apps.who.int/trialsearch/default.aspx</a>) (to 3 February 2015); </p> </li> <li> <p>American Society of Clinical Oncology conference abstracts (<a href="http://meetinglibrary.asco.org/" target="_blank">meetinglibrary.asco.org/</a>) (to 3 February 2015); </p> </li> <li> <p>Radiation Therapy Oncology Group (RTOG) clinical trials protocols (<a href="https://www.rtog.org/ClinicalTrials/Welcome.aspx" target="_blank">www.rtog.org/ClinicalTrials/Welcome.aspx</a>) (to 3 February 2015). </p> </li> </ul> </p> </section> </section> <section id="CD010341-sec-0041"> <h3 class="title" id="CD010341-sec-0041">Data collection and analysis</h3> <section id="CD010341-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SF, KC) independently screened the titles and abstracts (when available) of all reports identified through the electronic searches for eligibility. For studies appearing to meet the inclusion criteria, or for which there were insufficient information in the title and abstract to make a clear decision, we obtained the full report. Two review authors (HW, JW) independently assessed the full reports obtained from all the electronic and other methods of searching and resolved any disagreements on the eligibility of studies through discussion and consensus. Where resolution was not possible, we consulted a third review author. </p> <p>We recorded studies rejected at this or subsequent stages, and the reasons for exclusion, in the <a href="./references#CD010341-sec-0165" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD010341-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We included head and neck cancer trials with only combined data (i.e. no outcome data available by primary tumour site) where greater than 50% of participants presented with OC or OP cancer in this review. However, where separate 'pure' OC/OP cancer data were available for a trial, we extracted and analysed these 'pure' data and ignored the combined head and neck data. Where possible, we analysed OC and OP cancer data separately. </p> <p>Two review authors independently collected study details and outcomes data in duplicate and entered them into the <a href="./references#CD010341-sec-0164" title="">Characteristics of included studies</a> tables. We discussed any disagreement and consulted a third review author where necessary. If required, we contacted authors for clarification or to obtain missing information. </p> <p>We extracted the following data:</p> <p> <ul id="CD010341-list-0005"> <li> <p>year of publication, country of origin, number of centres, source of study funding, recruitment period; </p> </li> <li> <p>details of the participants including demographic characteristics and criteria for inclusion and exclusion, proportion with OC and OP cancer, numbers randomised to each treatment group; </p> </li> <li> <p>details of the type of intervention, timing, dose, mode of administration and duration;</p> </li> <li> <p>details of other concomitant treatments;</p> </li> <li> <p>details of the outcomes reported, including method of assessment, and time(s) assessed;</p> </li> <li> <p>sample size calculations.</p> </li> </ul> </p> </section> <section id="CD010341-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently carried out an assessment of the risk of bias of the included studies using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD010341-bbs2-0111" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We assessed the following six domains for each included study: random sequence generation, allocation concealment, blinding (of participants and outcome assessors), completeness of outcome data, risk of selective outcome reporting and risk of other potential sources of bias. </p> <p>We assessed risk of bias according to the following.</p> <p> <ul id="CD010341-list-0006"> <li> <p>Sequence generation: use of a random number table, use of a computerised system, central randomisation by statistical co‐ordinating centre, randomisation by an independent service using minimisation technique, permuted block allocation or Zelen technique was assessed as low risk of bias. If the paper merely stated randomised or randomly allocated with no further information this domain was assessed as being unclear. </p> </li> <li> <p>Allocation concealment: centralised allocation including access by telephone call or fax, or pharmacy‐controlled randomisation, sequentially numbered, sealed, opaque envelopes was assessed as low risk of bias. If allocation concealment was not mentioned this was assessed as unclear. </p> </li> <li> <p>Blinding: in many studies it may not be possible to blind participants and their carers to the allocated intervention. Outcome assessor blinding is usually possible. If studies were described as double blind, we assumed that participants and outcome assessors were blinded. If blinding was not mentioned, we assumed that no blinding occurred and assessed the study at high risk of bias for subjective outcomes. For the outcome of total mortality, it is unlikely that absence of blinding would introduce a bias. </p> </li> <li> <p>Outcome data: in trials of treatment for cancer it is rare that all participants randomised are included in the analysis of the outcome(s). Therefore, trials where both numbers and reasons of attrition were similar in each group, and a valid explanation was given, were assessed as being at low risk of bias due to incomplete outcome assessment. Where explanations were not given for exclusions from each group or where these explanations were invalid, or where rates and reasons were different for each group, the risk of bias due to (in)complete outcome data was assessed as unclear or high. </p> </li> <li> <p>Selective outcome reporting: a trial was assessed as being at low risk of bias due to selective outcome reporting, if the outcomes described in the methods section were systematically reported in the results section. Where reported outcomes did not include pre‐specified outcomes or expected in trials of treatments for oral cancers, or where additional analyses were reported this domain was assessed as unclear. Where results were inconsistently reported, we assessed the trial at high risk of bias. </p> </li> <li> <p>Other bias: imbalance in potentially important prognostic factors between the treatment groups at baseline, or the use of a co‐intervention in only one group (e.g. nasogastric feeding) are examples of potential sources of bias noted. </p> </li> </ul> </p> <p>Having taken into account the additional information provided by the authors of the trials, we placed each study into one of the following categories. </p> <p> <ul id="CD010341-list-0007"> <li> <p>Low risk of bias in all domains (plausible bias unlikely to seriously alter the results).</p> </li> <li> <p>Unclear risk of bias if one or more of the domains were assessed as unclear.</p> </li> <li> <p>High risk of bias (plausible bias that weakens confidence in the results) if one or more domains were assessed at high risk of bias. </p> </li> </ul> </p> </section> <section id="CD010341-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>The primary outcome was total mortality expressed as a hazard ratio (HR) (it is acknowledged that it is preferable to talk in terms of overall survival, however, statistically the estimate of effect is the HR of death). If studies did not quote HRs, we calculated the log HR and the standard error (SE) from the available summary statistics or Kaplan‐Meier curves, according to the methods proposed by <a href="./references#CD010341-bbs2-0124" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analysis of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>, or we requested these data from authors. </p> <p>For dichotomous outcomes at specific time points, we expressed the estimates of effect of an intervention as risk ratios (RR) together with 95% confidence intervals (CI). We only used dichotomous data for outcomes where HRs were unavailable or could not be calculated. If we had encountered continuous data, we would have used mean differences to express the estimate of effect, or standardised mean differences if multiple scales had been used by included studies assessing the same outcome. </p> </section> <section id="CD010341-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial authors to retrieve missing data when they were not available from the trial report or to clarify areas where data or trial design and conduct were unclear. </p> </section> <section id="CD010341-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the significance of any discrepancies in the estimates of the treatment effects from the different trials using Cochrane's test for heterogeneity and the I<sup>2</sup> statistic, and we investigated any heterogeneity. I<sup>2</sup> values over 50% indicated moderate to high heterogeneity (<a href="./references#CD010341-bbs2-0110" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). We considered heterogeneity statistically significant if the P value was less than 0.10 for the Chi<sup>2</sup> test. </p> </section> <section id="CD010341-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the reporting of research findings is influenced by the nature and direction of the findings of the research. We attempted to minimise potential reporting biases including publication bias, multiple (duplicate) publication bias and language bias in this review by conducting a sensitive search of multiple sources with no restriction on language. We also searched for ongoing trials and unpublished trials. </p> <p>If there were more than 10 studies in any one outcome, we had planned to construct a funnel plot and investigate any asymmetry detected. </p> </section> <section id="CD010341-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We conducted meta‐analyses where there were studies of similar comparisons reporting the same outcome measures. We planned to combine RRs for dichotomous data, and HRs for survival data, using a fixed‐effect model, unless there were four or more trials to be combined, when we would have used a random‐effects model. We entered HR data into the meta‐analysis using the inverse variance method. </p> </section> <section id="CD010341-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to the different natural history and treatment regimens for OC and OP cancers, we planned to analyse these cancer types separately if there were sufficient data available. We undertook a subgroup analysis based on the type of standard therapy (CRT or RT), given that these different standard therapies may well have differing effects on the efficacy of the targeted therapies and immunotherapies (<a href="./references#CD010341-bbs2-0095" title="DittmannK , MayerC , FehrenbacherB , SchallerM , RajuU , MilasL , et al. Radiation‐induced epidermal growth factor receptor nuclear import is linked to activation of DNA‐dependent protein kinase. Journal of Biological Chemistry2005;280(35):31182‐9. ">Dittmann 2005</a>; <a href="./references#CD010341-bbs2-0119" title="NakataE , HunterN , MasonK , FanZ , AngKK , MilasL . C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. International Journal of Radiation Oncology2004;59(4):1163‐73. ">Nakata 2004</a>). </p> </section> <section id="CD010341-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>If a sufficient number of studies had been included in any meta‐analyses, we would have undertaken sensitivity analyses to assess the robustness of the results by excluding studies with an unclear or high risk of overall bias. </p> <section id="CD010341-sec-0052"> <h5 class="title">Presentation of main results</h5> <p>We developed 'Summary of findings' tables for the main outcomes of this review (overall survival, locoregional control, disease‐free survival, progression‐free survival and adverse events) following GRADE methods (<a href="./references#CD010341-bbs2-0104" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">GRADE 2004</a>), and using GRADEPro software (<a href="./references#CD010341-bbs2-0105" title="BrozekJ , OxmanA , SchunemannH . GRADEpro. Version 3.6 for Windows. Grade Working Group, 2012. ">GRADEpro 2012</a>). We assessed the quality of the body of evidence with reference to the overall risk of bias of the included studies, directness of the evidence, inconsistency of the results, precision of the estimates and risk of publication bias. We assessed the quality of the body of evidence for each comparison and main outcome as high, moderate, low or very low. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010341-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010341-sec-0053"></div> <section id="CD010341-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD010341-sec-0055"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded a combined total of 4995 references and we identified a further 143 additional references. We discarded all but 110 references as not meeting the inclusion criteria. We obtained full‐text copies of these 110 potentially relevant studies. We excluded 71 full‐text articles relating to 60 studies and recorded the reasons for exclusion in the <a href="./references#CD010341-sec-0165" title="">Characteristics of excluded studies</a> table. </p> <p>We added five references to four studies to the <a href="./references#CD010341-sec-0166" title="">Characteristics of studies awaiting classification</a> table of this review. We sent emails to the authors of these studies requesting further information, as detailed in the tables. </p> <p>We found four trials to be ongoing and therefore added their details to the <a href="./references#CD010341-sec-0167" title="">Characteristics of ongoing studies</a> table. </p> <p>Thirty references to 12 studies met the inclusion criteria for this review (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). </p> <p>We present the study selection process as a flow chart in <a href="#CD010341-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010341-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review flow diagram" data-id="CD010341-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review flow diagram</p> </div> </div> </div> </section> <section id="CD010341-sec-0056"> <h4 class="title">Included studies</h4> <section id="CD010341-sec-0057"> <h5 class="title">Characteristics of the trials and settings</h5> <p>The studies included in this review were conducted in Cuba (<a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>), Germany (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>), Italy (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>), India (<a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>), Korea (<a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>), and the US (<a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>). Four studies were completed internationally in more than one country (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a> (two countries); <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a> (15); <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> (eight); <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> (nine)). The majority of the included studies were multicentred with two to 150 participating institutions (10 studies); two trials were single centre (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). The recruitment period ranged from one to six years with the most recent study recruiting in 2011 (<a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>). Four trials stated that they were phase‐III trials (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); five stated that they were phase‐II trials (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>); one stated that it was a phase‐I study (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>). The trial phase was not stated in the other two trials (<a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). </p> </section> <section id="CD010341-sec-0058"> <h5 class="title">Characteristics of the participants</h5> <p>Participants in the included studies were adults with squamous cell carcinomas of the OC or oropharynx. Where a trial recruited participants with head and neck cancers, at least 50% of participants in each included study had a primary tumour in the OC or oropharynx. Nine studies included both OC and OP cancers, which were diagnosed in at least 50% of the total participants. Two studies did not evaluate OC cancer, but the majority of participants had OP cancer (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>). One study evaluated mostly OC cancer (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>), while <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a> only recruited people with OC cancers. The 12 studies enrolled 2488 participants. Of these, 12% were diagnosed with OC cancer and 59% with OP cancer. The distribution of primary tumours in the included studies is summarised in the table below. </p> <p> <div class="table" id="CD010341-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention evaluated</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants (n) </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oral cavity (n (%))</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Oropharynx (n (%))</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Larynx (n (%))</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypopharynx (n (%))</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other (n (%))</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Monoclonal antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>940</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>659 (70.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215 (22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>424</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254 (60)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (15.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (44.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (26.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (19.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (54.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (5.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (17.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Tyrosine kinase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (6.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (48.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (11.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (30.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (3.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 (67)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (100)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Immunotherapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 (62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> </div> </p> <p>The cancer stage at study start was not reported in three studies (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>), and the remaining studies all included participants in stages III to IV. Nine studies provided information on tumour extent (TNM classification): TX to T4 (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>), T0 to T4 (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>), T1 to T4 (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>), T1 to T2 (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>), and T2 to T4 (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>). </p> </section> <section id="CD010341-sec-0059"> <h5 class="title">Characteristics of the interventions and comparisons</h5> <p>We grouped the studies included in this review into three comparisons based on the type of intervention being evaluated. </p> <section id="CD010341-sec-0060"> <h6 class="title">Comparison 1: Monoclonal antibodies</h6> <p>Five studies evaluated two different mAb, both against EGFR. Three studies evaluated cetuximab (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>), and two evaluated nimotuzumab (<a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). <a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a> compared the use of RT and cisplatin with or without cetuximab (400 mg/m<sup>2</sup> loading dose followed by weekly 250 mg/m<sup>2</sup> doses for six to seven weeks) while <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a> evaluated cetuximab (400 mg/m<sup>2</sup> loading dose followed by weekly 250 mg/m<sup>2</sup> doses for the duration of RT) in conjunction with one of two possible RT regimens. <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> compared docetaxel, cisplatin and cetuximab (400 mg/m<sup>2</sup> loading dose followed by weekly 250 mg/m<sup>2</sup> doses for nine weeks) with docetaxel and cisplatin alone. </p> <p><a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> randomised two groups of participants, those due to receive CRT and those due to receive RT, to either nimotuzumab (intravenous, 4 x 50 mg dilution in saline, one day/week for six weeks) plus standard therapy or standard therapy alone. Therefore, in this study there were two randomised comparisons, nimotuzumab plus CRT versus CRT alone and nimotuzumab plus RT versus RT alone. None of these four trials used a placebo control. <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a> evaluated nimotuzumab (intravenous, 250 mL in saline, one day/week for six weeks) plus RT compared with RT plus a placebo control in people with advanced disease who were considered unfit for CRT. </p> </section> <section id="CD010341-sec-0061"> <h6 class="title">Comparison 2: Tyrosine kinase inhibitors</h6> <p>Four trials evaluated three different tyrosine kinase inhibitors administered concomitantly with standard therapy (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> evaluated oral gefitinib versus placebo at two different doses (250 or 500 mg/day versus placebo) administered concomitantly with CRT and then continued for a two‐year maintenance phase. <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a> evaluated gefitinib plus RT versus RT alone. However, in this study, only a single dose (250 mg/day) was trialled, and no placebo was used. In another international phase II study, <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> evaluated lapatinib 1500 mg/day orally versus placebo administered concomitantly with CRT, and then continued as sole therapy in a maintenance phase lasting up to two years. In the remaining study in this group, <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>, participants started treatment with erlotinib 150 mg/day administered orally or via a percutaneous endogastric tube one week prior to the start of CRT. There was no placebo used and no maintenance phase in this study. </p> </section> <section id="CD010341-sec-0062"> <h6 class="title">Comparison 3: Immunotherapy</h6> <p>Three studies evaluated non‐specific immunotherapies (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>). Two studies evaluated interleukins using different regimens (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>). <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a> allocated participants to three cycles of either cisplatin chemotherapy (Al Sarraf regimen) or cisplatin chemotherapy plus 4.5 mIU/day rIL‐2 subcutaneously on days eight to 12, and 15 to 19 of each three‐week cycle. Following neoadjuvant chemotherapy, participant response was evaluated and the most appropriate locoregional treatment was then given ‐ surgery or RT, or both. </p> <p>In <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>, participants randomised to the interleukin group received injections of 5000 units of rIL‐2 around the ipsilateral cervical lymph node chain daily for 10 days prior to surgery. After surgery (and RT for people with lymph node metastases), contralateral five‐day courses of rIL‐2 were administered monthly for one year. Neither rIL‐2 trial used a placebo. </p> <p>The trial reported in <a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a> was conducted in the late 1970s (actual dates unclear) and evaluated Bacillus Calmette‐Guérin (BCG) cell wall preparation (BCG‐CWP). This was a first‐in‐humans study following promising laboratory results on animal cell lines. We included this trial for completeness. Participants allocated to the BCG‐CWP group received intratumoural injections of 3 mg of preparation in a volume of 0.5 to 2 mL, injected under local anaesthesia in a fan‐like pattern. When the inflammatory infiltrate had subsided, the participants underwent surgery. The control group did not receive a placebo but progressed directly to surgery. </p> </section> </section> <section id="CD010341-sec-0063"> <h5 class="title">Characteristics of the outcomes</h5> <p>We were unable to obtain the outcome data for the comparisons of interest for <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> , as the study reported outcomes for various combinations of allocated treatments and there was no reply to our email enquiry requesting outcome data by randomised group. For <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>, in the study report for the outcome of overall survival the nimotuzumab plus CRT versus CRT alone groups (46 participants), the P value showed a significant difference between the two groups (P value = 0.0078) and yet this was not reflected in the HR, which falls outside of the given 95% CI (HR 0.36; 95% CI 0.37 to 1.56). For the nimotuzumab plus RT versus RT alone groups, the difference between the groups was not significant (P value = 0.45), yet the addition of nimotuzumab caused a 24% reduction in death risk (HR 0.76; 95% CI 0.16 to 0.79). A very different HR was calculated from the survival curves presented on page 503 of the paper (HR 1.09). The authors did not respond to requests for additional information. As a result, we did not feel confident in these values and decided to omit them from the analyses. </p> <section id="CD010341-sec-0064"> <h6 class="title">Primary outcomes</h6> <section id="CD010341-sec-0065"> <p><b>Overall survival</b></p> <p>All of the included studies reported overall survival with the exception of <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>. HRs for mortality were reported or could be calculated for the comparisons of interest in six studies (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). </p> <p>We were unable to obtain the outcome data for the comparisons of interest to this review for <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>. The outcome data were incorrectly reported in the case of <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>. <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> and <a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a> reported the numbers alive after three years, and <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a> reported mean overall survival in each group. </p> </section> <section id="CD010341-sec-0066"> <p><b>Locoregional control</b></p> <p>Three studies reported HRs for locoregional control (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>). One study reported response to treatment (either complete or partial response) (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>). </p> </section> <section id="CD010341-sec-0067"> <p><b>Disease‐free survival</b></p> <p>Only two studies reported disease‐free survival (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). We were able to calculate HRs for this outcome for both of these studies. </p> </section> <section id="CD010341-sec-0068"> <p><b>Progression‐free survival or time to recurrence</b></p> <p>Five studies reported progression‐free survival (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>). We were able to use HRs from all of these studies in our analyses with the exception of <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> for the reasons stated above. </p> </section> </section> <section id="CD010341-sec-0069"> <h6 class="title">Secondary outcomes</h6> <section id="CD010341-sec-0070"> <p><b>Adverse events</b></p> <p>Across the 12 included studies (2488 participants), data from 2400 participants (96%) contributed to the reporting of adverse events, across a broad range of interventions and standard therapies, and assessed by a variety of toxicity evaluation assessment tools. </p> <p>Of the toxicity evaluation assessment tools used:</p> <p> <ul id="CD010341-list-0008"> <li> <p>five studies (42%) used the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3) (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>); </p> </li> <li> <p>two studies (17%) did not report their toxicity assessment method (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>); </p> </li> <li> <p>two studies (17%) used a country‐specific variant of the Common Toxicity Criteria of the National Cancer Institute (Canada: <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; US: <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>); </p> </li> <li> <p>one study (8%) singularly used the Toxicity criteria of the RTOG (1995) (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>); </p> </li> <li> <p>one study (8%) singularly used the WHO Recommendations for Grading of Acute and Subacute Toxicity (1981) (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); and </p> </li> <li> <p>one study (8%) used a combination of Toxicity criteria of the RTOG (1995) and WHO Recommendations for Grading of Acute and Subacute Toxicity (1981) (<a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). </p> </li> </ul> </p> </section> <section id="CD010341-sec-0071"> <p><b>Quality of life</b></p> <p>Only one study comprehensively assessed quality of life (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>). This study used two validated instruments to assess the multiple dimensions of quality of life: European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire (EORTC QLQ‐C30 (version 3.0)) and the section specifically designed for assessing people with head and neck cancers, Quality of Life Questionnaire ‐ Head &amp; Neck 35 (QLQ‐H&amp;N35) instruments) (<a href="./references#CD010341-bbs2-0086" title="BjordalK , deGraeffA , FayersPM , HammerlidE , vanPottelsbergheC , CurranD , et al. A 12 country field study of the EORTC QLQ‐C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ‐H&amp;N35) in head and neck patients. EORTC Quality of Life Group. European Journal of Cancer2000;36(14):1796‐807. [PUBMED: 10974628] ">Bjordal 2000</a>). Planned assessments were made at baseline, in week four of treatment, and at follow‐up visits in months four, eight and 12, after the start of treatment. At least one questionnaire was completed by most of the participants in the trial (419/424 participants). </p> </section> <section id="CD010341-sec-0072"> <p><b>Indirect costs to participants and health services and participant satisfaction</b></p> <p>No included studies addressed direct and indirect costs to participants and health services or participant satisfaction. </p> </section> </section> </section> </section> <section id="CD010341-sec-0073"> <h4 class="title">Excluded studies</h4> <p>We excluded 60 studies from this review and the reasons are noted in the <a href="./references#CD010341-sec-0165" title="">Characteristics of excluded studies</a> table. The reasons for exclusion can be summarised as follows. </p> <p> <ul id="CD010341-list-0009"> <li> <p>Evaluated adjuvant therapy: 16 studies (<a href="./references#CD010341-bbs2-0016" title="BalaramP , PadmanabhanTK , VasudevanDM . Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. II. Lymphocyte subpopulations. Neoplasma1988; Vol. 35, issue 2:235‐42. ">Balaram 1988</a>; <a href="./references#CD010341-bbs2-0017" title="BurtnessB , BourhisJP , VermorkenJB , HarringtonKJ , CohenEE . Afatinib versus placebo as adjuvant therapy after chemoradiation in a double‐blind, phase III study (LUX‐Head &amp;Neck 2) in patients with primary unresected, clinically intermediate‐to‐high‐risk head and neck cancer: study protocol for a randomized controlled trial. Trials2014;15:469. ">Burtness 2014</a>; <a href="./references#CD010341-bbs2-0028" title="HarariPM , HarrisJ , KiesMS , MyersJN , MachtayM , RotmanMZ , et al. Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high‐risk squamous cell carcinoma of the head and neck (RTOG 0234). International Journal of Radiation Oncology, Biology, Physics2007; Vol. 69, issue 3 Suppl 1:Abstract 22. ">Harari 2007</a>; <a href="./references#CD010341-bbs2-0029" title="HarringtonKJ , TemamS , D'CruzA , JainMM , D'OnofrioI , ManikhasGM , et al. A randomized, blinded, placebo (P)‐controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH‐RT) in high‐risk patients with squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2014;32:5. ">Harrington 2014</a>; <a href="./references#CD010341-bbs2-0032" title="KiesMS , HarrisJ , RotmanMZ , MyersJN , FooteRL , MachtayM , et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high‐risk squamous cell carcinoma of the head and neck (RTOG 0234). International Journal of Radiation Oncology, Biology, Physics2009; Vol. 75, issue 3:S14‐5. ">Kies 2009</a>; <a href="./references#CD010341-bbs2-0034" title="LiuS , ChenP , HuM , TaoY , ChenL , LiuH , et al. Phase II study of post‐surgery radiotherapy combined with recombinant adeno‐viral human p53 gene therapy in treatment of oral cancer. Journal of Cancer Science &amp; Therapy2012; Vol. 4:193‐5. ">Liu 2012</a>; <a href="./references#CD010341-bbs2-0035" title="MantovaniG , GhianiM , BianchiA , CurreliL , ContiniL , MacciòA , et al. The immunological assessment of a combined therapeutic approach (chemo‐ + radiotherapy +/‐ surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage [Italian]. Recenti Progressi in Medicina1995; Vol. 86, issue 1:8‐16. ">Mantovani 1995</a>; <a href="./references#CD010341-bbs2-0036" title="MesiaR , RuedaA , VeraR , LozanoA , MedinaJ , Aguiar BujandaD . Safety report of a randomized phase II trial to evaluate the combination of cetuximab plus accelerated concomitant boost radiotherapy (RT) followed or not followed by cetuximab monotherapy in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx. Journal of Clinical Oncology2008;26 Suppl:Abstract 6076. MesiaR , RuedaA , VeraR , LozanoA , MedinaJA , Aguiar BujandaD , et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial. Journal of Clinical Oncology2010;28 Suppl:Abstract 5534. MesiaR , RuedaA , VeraR , LozanoA , MedinaJA , AguiarD , et al. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. Annals of Oncology. 2012/10/09 2013; Vol. 24, issue 2:448‐53. ">Mesía 2013</a>; <a href="./references#CD010341-bbs2-0043" title="HarariP . Randomized phase II/III trial of surgery and postoperative radiation delivered with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high‐risk squamous cell cancer of the head and neck. Clinicaltrials.gov/show/NCT01810913(accessed May 2015). ">NCT01810913</a>; <a href="./references#CD010341-bbs2-0044" title="ChungC . A randomized, placebo controlled phase II trial of afatinib (BIBW2992) as adjuvant therapy following chemoradiation in patients with head and neck squamous cell carcinoma at high risk of recurrence. Clinicaltrials.gov/ct2/show/NCT01824823(accessed February 2015). ">NCT01824823</a>; <a href="./references#CD010341-bbs2-0049" title="PadmanabhanTK , BalaramP , VasudevanDM . Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. I. A three‐year clinical follow up. Neoplasma1987; Vol. 34, issue 5:627‐32. ">Padmanabhan 1987</a>; <a href="./references#CD010341-bbs2-0050" title="PapacR , MinorDR , RudnickS , SolomonLR , CapizziRL . Controlled trial of methotrexate and Bacillus Calmette‐Guérin therapy for advanced head and neck cancer. Cancer Research1978; Vol. 38, issue 10:3150‐3. ">Papac 1978</a>; <a href="./references#CD010341-bbs2-0052" title="SakaiSI . Adjuvant immunotherapy in head and neck tumours. A randomized study. HNO‐Praxis1986; Vol. 11, issue 2:109‐14. ">Sakai 1986</a>; <a href="./references#CD010341-bbs2-0061" title="TaylorIS , SissonGA , BytellDE . A randomized trial of adjuvant immunotherapy in squamous‐cell cancer of the head and neck. Head and Neck Surgery1981; Vol. 3, issue 4:351. TaylorIS , SissonGA , BytellDE . Adjuvant BCG in head and neck squamous cancer: a randomized trial. Proceedings of the American Society of Clinical Oncology1982; Vol. 1:C‐761. TaylorIS , SissonGA , BytellDE , Raynor JrWJ . A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Archives of Otolaryngology1983; Vol. 109, issue 8:544‐9. TaylorSG , SissonGA , BytellDE . Adjuvant chemoimmunotherapy of head and neck cancer. Recent Results in Cancer Research1978; Vol. 68:297‐308. TaylorSGI , PrachandS , NisiusS , KautzJ . Immunologic monitoring during a randomized study of adjuvant chemoimmunotherapy of head and neck cancer. Proceeds of the American Association for Cancer Research1978; Vol. 19:No‐413. TaylorSGI , SissonGA , BytellDE , ShettyR . A randomized trial of adjuvant immunotherapy in squamous cancer of the head and neck. Clinical Research1979; Vol. 27, issue 2:392A. ">Taylor 1978</a>; <a href="./references#CD010341-bbs2-0062" title="ThariatJ , BensadounR , Etienne‐GrimaldiM , GrallD , Penault‐LlorcaF , DassonvilleO , et al. Predicting the response to EGFR tyrosine kinase inhibitor gefitinib in head‐and‐neck cancer‐the carissa gortec 2004‐02 study. International Journal of Radiation Oncology, Biology, Physics2012; Vol. 84 Suppl:S21. ThariatJ , BensadounRJ , Etienne‐GrimaldiMC , GrallD , Penault‐LlorcaF , DassonvilleO , et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004‐02). Clinical Cancer Research. 2012/08/03 2012; Vol. 18, issue 18:5123‐33. [1078‐0432: (Print)] ThariatJ , DeRaucourtD , GiraudP , PeyradeF , DassonvilleO , CosmidisA , et al. Compliance and toxicity profiles of the CARISSA trial of postoperative cisplatin‐based chemoradiation +/‐ gefitinib in head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:e22152. ">Thariat 2012</a>; <a href="./references#CD010341-bbs2-0065" title="WaneboHJ , HilalEY , StrongEW , PinskyCM , MikeV , OettgenHF . Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Recent Results in Cancer Research1979; Vol. 68:324‐33. ">Wanebo 1979</a>). </p> </li> <li> <p>Less than 50% of participants had OC or OP cancers: nine studies (<a href="./references#CD010341-bbs2-0014" title="AmielJL , SanchoGH , VandenbrouckC , EschwegeF , DrozJP , SchwaabG , et al. First results of a randomized trial on immunotherapy of head and neck tumours. Recent Results in Cancer Research1979; Vol. 68:318‐23. ">Amiel 1979</a>; <a href="./references#CD010341-bbs2-0015" title="AndreadisC , EliopoulouC , KyrgidisA , BoukovinasI , NtomouchtsisA , KynigouM , et al. Phase II safety and toxicity study of cisplatin with or without cetuximab and concomitant radiotherapy for locoregionally advanced squamous cell carcinomas of the head and neck (SCCHN). Unpublished data relating to trial NCT01301248 (as supplied 17 June 2015). Individual patient data (as supplied 1 April 1995) Data on file. ">Andreadis 2015</a>; <a href="./references#CD010341-bbs2-0019" title="ChengVS , SuitHD , WangCC , RakerJ , KaufmanS , RothmanK , et al. Clinical trial of Corynebacterium parvum (intra‐lymph‐node and intravenous) and radiation therapy in the treatment of head and neck carcinoma. Cancer1982; Vol. 49, issue 2:239‐44. ">Cheng 1982</a>; <a href="./references#CD010341-bbs2-0021" title="DenaroA , StivalaF , MazzarinoMC . Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy and radiotherapy [Italian]. Acta Otorhinolaryngologica Italica1994;14(6):611‐25. ">Denaro 1994</a>; <a href="./references#CD010341-bbs2-0046" title="NeifeldJP , TerzJJ , KaplanAM , Lawrence JrW . Adjuvant corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx. Journal of Surgical Oncology1985; Vol. 28, issue 2:137‐45. ">Neifeld 1985</a>; <a href="./references#CD010341-bbs2-0057" title="Steuer‐VogtMK , BonkowskyV , AmbroschP , ScholzM , NeiA , StrutzJ , et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. European Journal of Cancer2001; Vol. 37, issue 1:23‐31. ">Steuer‐Vogt 2001</a>; <a href="./references#CD010341-bbs2-0058" title="SuenJY , RichmanSP , LivingstonRB , HershEM , CraigR , TonymonK . Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. American Journal of Surgery1977; Vol. 134, issue 4:474‐8. ">Suen 1977</a>; <a href="./references#CD010341-bbs2-0070" title="XiaZJ , ChangJH , ZhangL , JiangWQ , GuanZZ , LiuJW , et al. Phase III randomized clinical trial of intratumoral injection of E1B gene‐deleted adenovirus (H101) combined with cisplatin‐based chemotherapy in treating squamous cell cancer of head and neck or esophagus [Chinese]. Ai Zheng2004;23(12):1666‐70. ">Xia 2004</a>; <a href="./references#CD010341-bbs2-0072" title="ZhangSW , XiaoSW , LiuCQ , SunY , SuX , LiDM , et al. Recombinant adenovirus‐p53 gene therapy combined with radiotherapy for head and neck squamous‐cell carcinoma [Chinese]. Chung‐Hua Chung Liu Tsa Chih2005; Vol. 27, issue 7:426‐8. ZhangSW , XiaoSW , LiuCQ , SunY , SuX , LiDM , et al. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus‐p53 combined with radiotherapy: a phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi2003;83(23):2023‐8. ">Zhang 2003</a>). </p> </li> <li> <p>Follow‐up less than six months: eight studies (<a href="./references#CD010341-bbs2-0020" title="DelCampoJM , HittR , SebastianP , CarracedoC , LokanathaD , BourhisJ , et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy‐naive patients with locally advanced squamous cell carcinoma of the head and neck. British Journal of Cancer2011; Vol. 105, issue 5:618‐27. DelCampoJM , SebastianP , HittR , CarracedoC , LokanathaD , BourhisJ , et al. Effect of lapatinib monotherapy on apoptosis and proliferation: results of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology2008; Vol. 19:217. ">Del Campo 2011</a>; <a href="./references#CD010341-bbs2-0026" title="BaumanJE , GrossND , GoodingWE , DengW , ThomasSM , WangL , et al. Neoadjuvant erlotinib, erlotinib‐sulindac, or placebo: a randomized double blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology2013;31 Suppl:Abstract 6051. GrandisJR , LaiSY , EsteveFR , KimSW , FerrisRL , GibsonMK . Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report. Journal of Clinical Oncology2008;26 Suppl:Abstract 6037. ">Grandis 2008</a>; <a href="./references#CD010341-bbs2-0027" title="GrossND , BaumanJE , GoodingWE , DenqW , ThomasSM , WangL , et al. Erlotinib, erlotinib‐sulindac versus placebo: a randomized, double‐blind, placebo‐controlled window trial in operable head and neck cancer. Clinical Cancer Research2014;20(12):3289‐98. ">Gross 2014</a>; <a href="./references#CD010341-bbs2-0038" title="MoskowitzHS , GoodingWE , ThomasSM , FreilinoML , GrossN , ArgirisA , et al. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncology2012; Vol. 48, issue 11:1136‐45. ">Moskowitz 2012</a>; <a href="./references#CD010341-bbs2-0056" title="SerafiniP , WeedD , VellaJ , DelafuenteA , GomezCR , RodriguezZ , et al. PDE5 inhibitors for the immune therapy of head and neck squamous cell carcinoma. Immunology2012; Vol. 137:719. ">Serafini 2012</a>; <a href="./references#CD010341-bbs2-0060" title="TangE , HuQ , ZhouB . Effect of local immunotherapy of interleukin 2(IL‐2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas [Chinese]. Hua Xi Kou Qiang Yi Xue Za Zhi2003; Vol. 21, issue 6:444‐6. ">Tang 2003</a>; <a href="./references#CD010341-bbs2-0067" title="William JrWN , WeberRS , LeeJJ , MyersJ , GinsbergLE , El‐NaggarAK , et al. Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: objective responses and clinical outcomes. Journal of Clinical Oncology2011; Vol. 29:Abstract 5520. ">William 2011</a>; <a href="./references#CD010341-bbs2-0071" title="YangK , WenY , WangC . Clinical application of anticancer nanoparticles targeting metastasis foci of cervical lymph nodes in patients with oral carcinoma [Chinese]. Hua Xi Kou Qiang Yi Xue Za Zhi2003;21(6):447‐50. ">Yang 2003</a>). </p> </li> <li> <p>Allocation not truly randomised: five studies (<a href="./references#CD010341-bbs2-0018" title="ChenC , KaneM , SongJ , CampanaJ , RabenA , HuK , et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. Journal of Clinical Oncology2007; Vol. 25, issue 31:4880‐6. ">Chen 2007</a>; <a href="./references#CD010341-bbs2-0023" title="GalperSL , DeshpandeH , RoseMG , DeckerRH . Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). Journal of Clinical Oncology2009; Vol. 27, issue 15S:Abstract e17030. ">Galper 2009</a>; <a href="./references#CD010341-bbs2-0059" title="SzpirglasH , ChastangC , BertrandJ , ChastangC . Adjuvant treatment of tongue and floor of the mouth cancers. In: BonadonnaG , MathéG , SalmonSE editor(s). Adjuvant Therapies and Markers of Post‐Surgical Minimal Residual Disease II. Adjuvant Therapies of the Various Primary Tumors. Vol 68. Heidelberg, Germany: Springer Berlin Heidelberg, 1979:309‐17. ">Szpirglas 1979</a>; <a href="./references#CD010341-bbs2-0064" title="VermorkenJB , RemenarE , Van DenWeyngaertD , LicitraL , AwadaA , ClementPM , et al. Feasibility of cetuximab plus sequential platinum‐based therapy (TPF‐&gt; CRT) in advanced squamous cell head and neck cancer (SCCHN): a randomized phase II study of the EORTC Head and Neck Cancer Group (EORTC‐HNCG # 24061). European Archives of Oto‐Rhino‐Laryngology2012; Vol. 269, issue 4:1332‐3. ">Vermorken 2012</a>; <a href="./references#CD010341-bbs2-0068" title="WolfGT , Fee JrWE , DolanRW , MoyerJS , KaplanMJ , SpringPM , et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head &amp; Neck2011; Vol. 33, issue 12:1666‐74. ">Wolf 2011</a>). </p> </li> <li> <p>Participants had metastatic or recurrent disease: four studies (<a href="./references#CD010341-bbs2-0024" title="GilbertJ , LeeJ , ArgirisA , FeldmanL , HaigentzM , BurtnessB , et al. Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology2009;27 Suppl:Abstract 6020. ">Gilbert 2009</a>; <a href="./references#CD010341-bbs2-0031" title="HuangW , WuJ , LinX , LiS , LiuR , HuW , et al. A multicenter, open‐label, randomized phase II trial of adenovirus‐mediated endostatin gene therapy in combination with paclitaxel and cisplatin chemotherapy in advanced head and neck carcinoma: preliminary results. Journal of Clinical Oncology2010;28 Suppl:Abstract e16005. ">Huang 2010</a>; <a href="./references#CD010341-bbs2-0051" title="RichmanSP , LivingstonRB , GuttermanJU , SuenJY , HershEM . Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study. Cancer Treatment Reports1976; Vol. 60, issue 5:535‐9. ">Richman 1976</a>; <a href="./references#CD010341-bbs2-0069" title="WoodsJE , DeSantoLW , RittsRE . A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck. Surgical Clinics of North America1977; Vol. 57, issue 4:769‐78. ">Woods 1977</a>). </p> </li> <li> <p>Publication contained insufficient information to include the study and no further information was available to review authors: three studies (<a href="./references#CD010341-bbs2-0054" title="SawakiS . Randomized trial of immunotherapy with OK‐432 in head and neck cancer. Journal of Cancer Research and Clinical Oncology1990; Vol. 116 Suppl:696. ">Sawaki 1990</a>; <a href="./references#CD010341-bbs2-0063" title="TsukudaM , SawakiS . The OK‐432 immunotherapy for head and neck carcinomas. Journal of Cancer Research &amp; Clinical Oncology1990; Vol. 116 Suppl:701. ">Tsukuda 1990</a>; <a href="./references#CD010341-bbs2-0066" title="WaraWM , WaraDW , AmmannAJ , BarnardJL , PhillipsTL . Immunosuppression and reconstitution with thymosin after radiation therapy. International Journal of Radiation Oncology, Biology, Physics1979; Vol. 5, issue 7:997‐1001. ">Wara 1979</a>). </p> </li> <li> <p>Arms of the trial not comparable (other differences between the trial arms than targeted/immunotherapy): 10 studies (<a href="./references#CD010341-bbs2-0025" title="GiraltJ , TrigoJ , NuytsS , OzsahinM , SkladowskiK , HatoumG , et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous‐cell carcinoma of the head and neck (CONCERT‐2): a randomised, controlled, open‐label phase 2 trial. Lancet Oncology2015;16:221‐32. ">Giralt 2015</a>; <a href="./references#CD010341-bbs2-0030" title="HeukelomJ , HammingO , BartelinkH , HoebersF , GiraltJ , HerlestamT , et al. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer2013;13:84. ">Heukelom 2013</a>; <a href="./references#CD010341-bbs2-0037" title="MesíaR , HenkeM , FortinA , MinnH , Yunes AnconaAC , CmelakA , et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous‐cell carcinoma of the head and neck (CONCERT‐1): a randomised, controlled, open‐label phase 2 trial. Lancet Oncology2015;2:208‐20. ">Mesía 2015</a>; <a href="./references#CD010341-bbs2-0042" title="TrottiAM , GillisonM . RTOG 1016: radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer. Clinicaltrials.gov/show/NCT01302834(accessed May 2015). ">NCT01302834</a>; <a href="./references#CD010341-bbs2-0041" title="GeoffroisL . A phase III randomized multicenter study comparing an induction chemotherapy followed by irradiation and concurrent erbitux versus chemoradiotherapy for patients with locoregional advanced head and neck cancers. Clinicaltrials.gov/ct2/show/NCT01233843(accessed May 2015). ">NCT01233843</a>; <a href="./references#CD010341-bbs2-0045" title="Gebre‐MedhinM , SchönströmI . A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer. Clinicaltrials.gov/ct2/show/NCT01969877(accessed May 2015). ">NCT01969877</a>; <a href="./references#CD010341-bbs2-0040" title="SiuLL , WaldronJ . Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced stage III or stage IV head and neck cancer. Clinicaltrials.gov/ct2/show/NCT00820248(accessed May 2015). ">NCT00820248</a>; <a href="./references#CD010341-bbs2-0039" title="AdansaJC , CruzJJ , HittR . An open label randomized, multi‐centre phase III trial of TPF chemotherapy plus concomitant treatment with cisplatin and conventional radiotherapy versus TPF chemotherapy plus concomitant cetuximab and conventional radiotherapy in locally advanced, unresectable head and neck cancer. Clinicaltrials.gov/show/NCT00716391(accessed May 2015). ">NCT00716391</a>; <a href="./references#CD010341-bbs2-0048" title="GhiM , PaccagnellaA , OrecchiaR , ParisiS , BertoniF , MinguzziN , et al. Cetuximab/radiation therapy (CET + RT) versus concomitant chemoradiation therapy (CCHT + RT) with or without induction docetaxel/cisplatin/5fluorouracil (TPF) in locally advanced head‐and‐neck squamous cell carcinoma (LASCCHN) ‐ preliminary results on toxicity of a randomized, 2X2 factorial, phase II‐III study (NCT01086826) [abstract]. International Journal of Radiation Oncology, Biology, Physics2012; Vol. 84:S153. PaccagnellaA , GhiMG , FlorianiI , GavaA , BuffoliA . Concomitant chemoradiation or RT/cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: a randomized phase III factorial study. Journal of Clinical Oncology2011; Vol. 29 Suppl:Abstract TPS196. ">Paccagnella 2011</a>; <a href="./references#CD010341-bbs2-0053" title="SalamaJK , HarafDJ , StensonKM , BlairEA , WittME , WilliamsR , et al. A randomized phase II study of 5‐fluorouracil, hydroxyurea, and twice‐daily radiotherapy compared with bevacizumab plus 5‐fluorouracil, hydroxyurea, and twice‐daily radiotherapy for intermediate‐stage and T4N0‐1 head and neck cancers. Annals of Oncology2011; Vol. 22:2304‐9. ">Salama 2011</a>). </p> </li> <li> <p>Report was the protocol for a study not yet undertaken (<a href="./references#CD010341-bbs2-0047" title="OkamotoM . Randomized study for evaluation of antitumor effect of neoadjuvant therapy using radiation, S‐1 and OK‐432 in patients with oral squamous cell carcinoma. Biotherapy2007; Vol. 21, issue 5:322‐7. ">Okamoto 2007</a>). </p> </li> <li> <p>Study planned and then withdrawn (<a href="./references#CD010341-bbs2-0033" title="LiberatoscioliC , LangendijkJA , VanHerpenC , ColletteL , OzsahinEM , Karra GurunathR , et al. EORTC 22071‐24071: randomized, phase III trial of EGFR‐antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence. Journal of Clinical Oncology2011;29(15 Suppl 1):Abstract TPS197. ">Liberatoscioli 2011</a>). </p> </li> <li> <p>All randomised groups received cetuximab (<a href="./references#CD010341-bbs2-0055" title="SeiwertTY , HarafDJ , CohenEE , BlairEA , StensonK , SalamaJK , et al. A randomized phase II trial of cetuximab‐based induction chemotherapy followed by concurrent cetuximab, 5‐FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). Journal of Clinical Oncology2011; Vol. 29 Suppl:Abstract 5519. ">Seiwert 2011</a>). </p> </li> <li> <p>Review of trial without original data (<a href="./references#CD010341-bbs2-0022" title="FujiiM . Molecular targeting therapy for head and neck cancer [Japanese]. Japanese Journal of Cancer and Chemotherapy2013;40(7):867‐70. ">Fujii 2013</a>). </p> </li> <li> <p>No targeted therapy used (<a href="./references#CD010341-bbs2-0013" title="AghiliM , IzadiS , MojahedM , KazemianA , FarhanF , SamieiF . The role of COX‐2 inhibitor (CELECOXIB) in combination with chemo‐radiotherapy, in improvement of the survival and response rate in head and neck carcinoma, Phase III, randomized clinical trial (NCT00603759). Radiotherapy and Oncology2010; Vol. 96:S66. ">Aghili 2010</a>). </p> </li> </ul> </p> <p>We were unable to obtain sufficient information to determine whether four studies met our inclusion criteria (<a href="./references#CD010341-bbs2-0073" title="ArgirisA , OhrJ , KubicekG , DuvvuriU , HeronDE , KotsakisPA , et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E),and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2013;21:Abstract 6043. KotsakisAP , HeronDE , KubicekGJ , FerrisRL , KimS , GibsonMK , et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract TPS264. ">Argiris 2013</a>; <a href="./references#CD010341-bbs2-0074" title="BhatnagarAR , SinghDP , SharmaR , SharmaOP , SharmaS , GuptaS . A comparative study of monoclonal antibody against EGFR (nimotuzumab) used in combination with chemoradiation versus chemoradiation alone in the treatment of locally advanced inoperable squamous cell carcinoma of the head and neck. Journal of Clinical Oncology2012;30 Suppl:Abstract 51. ">Bhatnagar 2012</a>; <a href="./references#CD010341-bbs2-0075" title="NandwaniPK , VyasR , MehtaM , NeemaJ . Efficacy and toxicity of tyrosine kinase inhibitor along with platinum based concurrent chemoirradiation in locally advanced squamous cell carcinoma of head and neck. International Journal of Radiation Oncology, Biology, Physics2010;78(3 Suppl 1):S105. ">Nandwani 2010</a>; <a href="./references#CD010341-bbs2-0076" title="AstraZeneca . The IRESSA novel head and neck chemotherapy evaluation study. Clinicaltrials.gov/ct2/show/NCT00255476(accessed February 2015). ">NCT00255476</a>). Three were conference abstracts (<a href="./references#CD010341-bbs2-0073" title="ArgirisA , OhrJ , KubicekG , DuvvuriU , HeronDE , KotsakisPA , et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E),and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2013;21:Abstract 6043. KotsakisAP , HeronDE , KubicekGJ , FerrisRL , KimS , GibsonMK , et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract TPS264. ">Argiris 2013</a>; <a href="./references#CD010341-bbs2-0074" title="BhatnagarAR , SinghDP , SharmaR , SharmaOP , SharmaS , GuptaS . A comparative study of monoclonal antibody against EGFR (nimotuzumab) used in combination with chemoradiation versus chemoradiation alone in the treatment of locally advanced inoperable squamous cell carcinoma of the head and neck. Journal of Clinical Oncology2012;30 Suppl:Abstract 51. ">Bhatnagar 2012</a>; <a href="./references#CD010341-bbs2-0075" title="NandwaniPK , VyasR , MehtaM , NeemaJ . Efficacy and toxicity of tyrosine kinase inhibitor along with platinum based concurrent chemoirradiation in locally advanced squamous cell carcinoma of head and neck. International Journal of Radiation Oncology, Biology, Physics2010;78(3 Suppl 1):S105. ">Nandwani 2010</a>), and attempts to contact the study authors for further information were unsuccessful. One was a large international trial conducted by the pharmaceutical company that manufactures gefitinib (<a href="./references#CD010341-bbs2-0076" title="AstraZeneca . The IRESSA novel head and neck chemotherapy evaluation study. Clinicaltrials.gov/ct2/show/NCT00255476(accessed February 2015). ">NCT00255476</a>). As these are recent trials and results may be in the process of being published, we have categorised these trials as <a href="./references#CD010341-bbs1-0003" title="">Studies awaiting classification</a>. </p> </section> </section> <section id="CD010341-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD010341-fig-0002">Figure 2</a> and <a href="#CD010341-fig-0003">Figure 3</a> show a summary of our risk of bias assessments. </p> <div class="figure" id="CD010341-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010341-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010341-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010341-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010341-sec-0075"> <h4 class="title">Allocation</h4> <p>Nine of the included studies clearly described the method used to generate the randomisation sequence and conceal the randomisation schedule from the investigators; we assessed these studies as being at low risk of selection bias (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). Three studies provided no information except that allocation was randomised so we assessed these studies at unclear risk of selection bias (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). </p> </section> <section id="CD010341-sec-0076"> <h4 class="title">Blinding</h4> <p>Three studies used identical placebos so that participants were blinded to allocated treatment, so we assessed these studies at low risk of performance bias (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> ; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> ; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). Seven studies used no placebo so participants were aware of the allocated treatment (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>), and two studies did not mention placebo in the study reports (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a> ; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>). It is possible that knowledge of the allocated treatment by both the clinicians and participants may have influenced the amount or type of care or attention participants received or participants' perceptions of symptoms. However, some of our primary outcomes are largely objective and not participant reported (e.g. overall survival) and therefore we assessed these nine studies as being at unclear risk of performance bias. </p> <p>Outcome assessors were blinded to allocated treatment, or investigator‐generated data were submitted for blind review by an independent centralised committee of experts in seven studies, so we assessed these studies at low risk of detection bias (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). The remaining five studies did not report who assessed the outcomes and we assessed these studies at unclear risk of detection bias. </p> </section> <section id="CD010341-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed seven studies at low risk of attrition bias because the study reports indicated intention‐to‐treat analysis and clearly described the numbers of participants excluded or withdrawn in each group and the reasons for this ( <a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a> ; <a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a> ; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a> ; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> ; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a> ; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> ; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> did not report outcomes for each randomised group and it was difficult to determine the numbers of participants excluded from the analysis, so we assessed this study at unclear risk of attrition bias. We assessed <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> as being at unclear risk of attrition bias because the loss to follow‐up rationale was not reported for one trial arm. Attrition was high in <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>, although rationale was provided and a balance of participants lost‐to‐follow‐up reported across arms. We assessed this study at unclear risk of bias. In <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>, the information about number of participants included in outcome assessment was incomplete and the numbers of and reasons for withdrawals from the trial were not given. Therefore, we assessed this study as at high risk of attrition bias. Although the numbers of participants excluded from the analysis in each group were similar in <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>, the reasons given were different and likely to be associated with the allocated treatment, so we assessed this study as at high risk of attrition bias. </p> </section> <section id="CD010341-sec-0078"> <h4 class="title">Selective reporting</h4> <p>Seven studies reported the outcomes planned in the methods sections clearly and fully and we assessed them at low risk for reporting bias (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> and <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a> appeared to report some adverse events inconsistently and therefore we rated them at unclear risk of bias. <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> reported outcomes for some combinations of groups only and we were unable to obtain outcome data for each randomised group, so we assessed this study as at high risk of reporting bias. The HRs, CIs and P values reported in <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> for the outcomes of overall survival and progression‐free survival were inconsistent as described in detail under <a href="#CD010341-sec-0056">Included studies</a> (Characteristics of the outcomes) and therefore we assessed this study as high risk of bias. <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a> only partially reported secondary endpoints, so we assessed this study at high risk of reporting bias. </p> </section> <section id="CD010341-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other sources of bias in eight studies (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>). In <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>, an unplanned interim analysis resulted in early closure of study. However, guidance from <a href="./references#CD010341-bbs2-0111" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a> is that simulation evidence suggests that inclusion of stopped early trials in meta‐analyses will not lead to substantial bias. Therefore, we assessed these nine studies at low risk of other bias. In <a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>, the trialists recruited additional participants after interim results indicated control group demonstrated better PFS/DFS outcomes than anticipated, and the sample size was changed several times mid‐study. Therefore, we assessed this study at unclear risk of other bias.The quality of the trial report was poor in <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>. Due to poor quality information, we were unable to eliminate the presence of possible other biases and we assessed this study to be at unclear risk of other bias. Likewise, in <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>, the quality of the trial report was poor, perhaps due to translation into English. There was also incomplete reporting of some non‐outcome data (e.g. EGFR expression) in this study, and it was unclear why some participants had biopsies and others did not. Our attempts to obtain clarification from study authors were unsuccessful so we assessed this study at high risk of other sources of bias. </p> <p>Overall, we assessed the risk of bias at unclear in seven studies (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>), and high in the remaining five (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). </p> </section> </section> <section id="CD010341-sec-0080"> <h3 class="title" id="CD010341-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD010341-tbl-0001"><b>Summary of findings for the main comparison</b> Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity or oropharyngeal cancers</a>; <a href="./full#CD010341-tbl-0002"><b>Summary of findings 2</b> Tyrosine kinase inhibitors plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</a>; <a href="./full#CD010341-tbl-0003"><b>Summary of findings 3</b> Immunotherapy plus standard therapy versus standard therapy alone for the treatment of people with oral and oropharyngeal cancers</a> </p> <section id="CD010341-sec-0081"> <h4 class="title">Comparison 1: EGFR monoclonal antibodies plus standard therapy versus standard therapy alone </h4> <p>Five studies compared the addition of EGFR mAb to standard therapy (chemotherapy with or without RT) with standard therapy alone ( <a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a> ; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a> ; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> ; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> ; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a> ). Across these trials, 4% of participants had OC tumours and 65% had OP tumours. These five studies were separated into two subgroups; three studies compared the addition of EGFR mAb to CRT with CRT alone (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>), and two studies compared the addition of EGFR mAb to RT with RT alone (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>). </p> <p>Three trials evaluated cetuximab (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>), while <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a> and <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> evaluated nimotuzumab. <a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a> ; and <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> did not use a placebo in the control group, while <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a> used a placebo in a double‐blinded trial. We rated three of these studies at high risk of bias (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>), and two of these studies at unclear risk of bias (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>). </p> <p>The HRs, CIs and P values reported in <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> for the outcomes of overall survival and progression‐free survival were inconsistent as described in detail under <a href="#CD010341-sec-0056">Included studies</a> (Characteristics of the outcomes). Therefore, we have omitted the data from <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a> from the results section of this review. The data from <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> were obtained from a conference abstract and we were unable to obtain sufficient information to calculate an HR to include in the pooled analysis. The number of participants included in the trial was small (92 in total) and <a href="#CD010341-tbl-0005">Table 2</a> presents the data that we could obtain. </p> <div class="table" id="CD010341-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome data from Koh 2013</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Docetaxel + cisplatin + cetuximab (n = 48)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Docetaxel + cisplatin (n = 44)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS (3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (n = 33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PFS (3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% (n = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (n = 25)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT: intention to treat; n: number of participants; OS: overall survival; PFS: progression‐free survival. </p> </div> </div> <section id="CD010341-sec-0082"> <h5 class="title">Overall survival</h5> <p>Four studies provided outcome data for overall survival, although only three (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>; 1421 participants) reported data that we were able to use in a meta‐analysis. The pooled estimate for these three studies where 67% of participants had OP cancer showed evidence of a benefit for overall survival of adding mAb to standard therapy (HR 0.82; 95% CI 0.69 to 0.97; P value = 0.02) (<a href="./references#CD010341-fig-0004" title="">Analysis 1.1</a>). We assessed the quality of this evidence to be moderate. The data from <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> would appear to support this evidence (<a href="#CD010341-tbl-0005">Table 2</a>). </p> <p>We formed two subgroups: mAb therapy plus RT versus RT alone, and mAb therapy plus CRT versus CRT alone. However, although these subgroups report different results (the subgroup comparing mAb therapy plus RT versus RT alone (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>; two studies, 530 participants) reported a benefit in overall survival favouring mAb (HR 0.73; 95% CI 0.58 to 0.91; P value = 0.006) (<a href="./references#CD010341-fig-0004" title="">Analysis 1.1</a>) while the subgroup comparing mAb therapy plus CRT versus CRT (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; one study, 891 participants) alone showed no evidence of a change in overall survival (HR 0.95; 95% CI 0.74 to 1.23; P value = 0.70) (<a href="./references#CD010341-fig-0004" title="">Analysis 1.1</a>)), the difference between these subgroups was not significant (P value = 0.13; I<sup>2</sup> = 57.4%). </p> </section> <section id="CD010341-sec-0083"> <h5 class="title">Locoregional control</h5> <p>Only one study reported the outcome of locoregional control (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; 424 participants, 60% OP tumours). This showed a benefit favouring mAb (cetuximab) (HR 0.68; 95% CI 0.52 to 0.89; P value = 0.005) (<a href="./references#CD010341-fig-0005" title="">Analysis 1.2</a>). The paper reported that for people with OP tumours alone the HR was 0.61 (CI and P value not reported). We assessed the quality of this evidence to be moderate. </p> </section> <section id="CD010341-sec-0084"> <h5 class="title">Progression‐free survival</h5> <p>Three trials evaluating EGFR mAb reported the outcome of PFS (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>), although we were only able to obtain HRs from two studies (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>). </p> <p>Two subgroups were mAb therapy plus RT versus RT alone (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; one study, 424 participants, 60% OP tumours), and mAb therapy plus CRT versus CRT alone (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; one study, 891 participants, 70% OP tumours). The subgroup comparing mAb therapy plus RT versus RT alone reported a benefit favouring cetuximab (HR 0.70; 95% CI 0.54 to 0.91; P value = 0.007) (<a href="./references#CD010341-fig-0006" title="">Analysis 1.3</a>). However, the subgroup comparing mAb therapy plus CRT versus CRT alone reported no evidence of a difference in PFS (HR 1.08; 95% CI 0.89 to 1.32 ; P value = 0.42) (<a href="./references#CD010341-fig-0006" title="">Analysis 1.3</a>). There was a significant difference between these subgroups (P value = 0.008; I<sup>2</sup> = 86%). As a result, we were unable to pool data across subgroups. The PFS data at three years from <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a> suggested a benefit favouring cetuximab although no HRs were reported (<a href="#CD010341-tbl-0005">Table 2</a>). </p> </section> <section id="CD010341-sec-0085"> <h5 class="title">Adverse effects</h5> <p>The most commonly reported adverse effects from each study are listed below and in <a href="#CD010341-tbl-0006">Table 3</a>. </p> <div class="table" id="CD010341-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse event outcomes: comparison 1: monoclonal antibodies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (MH, 95% CI, P value)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity (P value; I<sup>2</sup>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1.6 Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1417</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not estimable due to high heterogeneity (P value = 0.0009; I<sup>2</sup> = 86%) between subgroups (cetuximab; nimotuzumab), and within the cetuximab subgroup (P value = 0.0002) I<sup>2</sup> = 93%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.96 to 1.51) (random effects) P value = 0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.07; I<sup>2</sup> = 58% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1.7 Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.92 to 1.03) (fixed effect) P value = 0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.60; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.83 to 1.04) (fixed effect) P value = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.26; I<sup>2</sup> = 26% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1.8 Xerostomia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.91 to 1.04) (fixed effect) P value = 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.61; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.36 (0.80 to 2.31) (fixed effect) P value = 0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.60; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>1.9 Skin toxicity/ acneiform rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value &lt; 0.00001; I<sup>2</sup> = 99.3%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (cetuximab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.56 (5.35 to 8.03) (fixed effect) P value &lt; 0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value = 0.080; I<sup>2</sup> = 66% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (nimotuzumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.85 to 1.31) P value = 0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value = 0.005; I<sup>2</sup> = 87.5%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (cetuximab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.72 (8.33 to 37.73) (fixed effect) P value &lt; 0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value = 0.56; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (nimotuzumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.01 to 4.05) P value = 0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; MH: Mantel‐Haenszel.</p> </div> </div> <section id="CD010341-sec-0086"> <h6 class="title">Mucositis</h6> <section id="CD010341-sec-0087"> <p><b>All grades</b></p> <p>Three studies (25% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>); 1417 participants; fixed‐effect analysis) compared the addition of mAbs to standard therapy with standard therapy alone (placebo used in one study). The evidence was inconclusive due to a considerable amount of heterogeneity (P value = 0.0009; I<sup>2</sup> = 86%) between the two subgroups (cetuximab, nimotuzumab), and within the cetuximab subgroup (P value = 0.0002; I<sup>2</sup> = 93%). </p> </section> <section id="CD010341-sec-0088"> <p><b>Grades 3 or higher</b></p> <p>Four studies (33% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>); 1495 participants; random‐effects analysis) compared the addition of mAbs to standard therapy with standard therapy alone (placebo used in one study). There was no evidence to refute or support an increase or reduction in mucositis occurrence at grades 3 or higher for participants treated with mAbs (RR 1.20; 95% CI 0.96 to 1.51; P value = 0.12). There was a substantial amount of heterogeneity (P value = 0.07; I<sup>2</sup> = 58%). </p> </section> </section> <section id="CD010341-sec-0089"> <h6 class="title">Dysphagia</h6> <section id="CD010341-sec-0090"> <p><b>All grades</b></p> <p>Three studies (25% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>); 1403 participants: fixed‐effect analysis) compared the addition of mAbs to standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in dysphagia occurrence across all grades for participants treated with mAbs (RR 0.97; 95% CI 0.92 to 1.03; P value = 0.37). There was no evidence of heterogeneity (P value = 0.60; I<sup>2</sup> = 0%). </p> </section> <section id="CD010341-sec-0091"> <p><b>Grades 3 or higher</b></p> <p>Three studies (25% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>); 1403 participants: fixed‐effect analysis) compared the addition of mAbs to standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in dysphagia occurrence at grades 3 or higher for participants treated with mAbs (RR 0.93; 95% CI 0.83 to 1.04; P value = 0.19). There was no evidence of heterogeneity (P value = 0.26; I<sup>2</sup> = 26%). </p> </section> </section> <section id="CD010341-sec-0092"> <h6 class="title">Xerostomia</h6> <section id="CD010341-sec-0093"> <p><b>All grades</b></p> <p>Three studies (25% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>); 1417 participants: fixed‐effect analysis) compared the addition of mAbs to standard therapy with standard therapy alone (placebo used in one study). There was no evidence to refute or support an increase or reduction in xerostomia occurrence across all grades for participants treated with mAbs (RR 0.97; 95% CI 0.91 to 1.04; P value = 0.46). There was no evidence of heterogeneity (P value = 0.61; I<sup>2</sup> = 0%). </p> </section> <section id="CD010341-sec-0094"> <p><b>Grades 3 or higher</b></p> <p>Two studies (17% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>); 1311 participants: fixed‐effect analysis) compared the addition of mAbs to standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in xerostomia occurrence at grades 3 or higher for participants treated with mAbs (RR 1.36; 95% CI 0.80 to 2.31; P value = 0.25). There was no evidence of heterogeneity (P value = 0.60; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010341-sec-0095"> <h6 class="title">Skin toxicity/acneiform rash</h6> <section id="CD010341-sec-0096"> <p><b>All grades</b></p> <p>Three studies (25% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>); 1403 participants: fixed‐effect analysis) compared the addition of mAbs to standard therapy with standard therapy alone (without placebo). There was a significant difference between the two (cetuximab, nimotuzumab) subgroups (P value &lt; 0.00001; I<sup>2</sup> = 99.3%). </p> <p>In the cetuximab subgroup, there was evidence of an increase in skin toxicity/acneiform rash occurrence across all grades (RR 6.56; 95% CI 5.35 to 8.03; P value &lt; 0.00001), and a substantial amount of heterogeneity (P value = 0.08; I<sup>2</sup> = 66%). There was no evidence to refute or support an increase or reduction in skin toxicity/acneiform rash occurrence across all grades in the nimotuzumab subgroup (RR 1.06; 95% CI 0.85 to 1.31; P value = 0.61). </p> </section> <section id="CD010341-sec-0097"> <p><b>Grades 3 or higher</b></p> <p>Four studies (33% (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>); 1495 participants; random‐effects analysis) compared the addition of mAbs to standard therapy with standard therapy alone (without placebo). There was a significant difference between the two (cetuximab, nimotuzumab) subgroups (P value = 0.005; I<sup>2</sup> = 87.5%). </p> <p>In the cetuximab subgroup, there was evidence of an increase in skin toxicity/acneiform rash occurrence at grades 3 or higher (RR 17.72; 95% CI 8.33 to 37.73; P value &lt; 0.00001), and no evidence of heterogeneity (P value = 0.56; I<sup>2</sup> = 0%). There was no evidence of a difference in skin toxicity/acneiform rash occurrence at grades 3 or higher in the nimotuzumab subgroup (RR 0.20; 95% CI 0.01 to 4.05; P value = 0.29). </p> </section> </section> </section> <section id="CD010341-sec-0098"> <h5 class="title">Quality of life</h5> <p>Only one study comprehensively assessed quality of life (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>, 424 participants). The mean best and worst post baseline score (with standard deviation) was reported for each treatment group; for global health status; and for the subscales of physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning, with higher scores indicating a higher level of functioning and better quality of life. There was no statistically significant difference between the groups for any of these measures. </p> </section> </section> <section id="CD010341-sec-0099"> <h4 class="title">Comparison 2: Tyrosine kinase inhibitors plus standard therapy versus standard therapy alone </h4> <p>Three included studies compared the addition of tyrosine kinase inhibitors to CRT with CRT alone (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>). <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a> compared the addition of gefitinib to RT versus RT alone. Three studies were at unclear risk of bias (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>), while one was at high risk of bias (<a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). Of the participants across all four studies that evaluated TKIs, 17% had OC tumours and 52% OP tumours. </p> <p>Two studies evaluated gefitinib (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>). <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a> evaluated gefitinib with RT and did not use a placebo control, while <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> did use a placebo control to evaluate oral gefitinib administered with CRT. We were unable to obtain outcome data for the comparisons of interest in the study by <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>, as these data were held by the pharmaceutical company that produces gefitinib. </p> <p><a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a> evaluated erlotinib with CRT and there was no placebo used in the control group. <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a> evaluated lapatinib with CRT in a placebo‐controlled trial. </p> <section id="CD010341-sec-0100"> <h5 class="title">Overall survival</h5> <p>There was no evidence of a difference in overall survival between groups receiving a TKI (either erlotinib or lapatinib) plus CRT and groups receiving CRT alone in the two phase‐II trials that evaluated this comparison (<a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; 271 participants, 66% OP tumours, 7% OC tumours) (HR 0.99; 95% CI 0.62 to 1.57; P value = 0.95) (<a href="./references#CD010341-fig-0007" title="">Analysis 2.1</a>). We assessed the quality of this evidence to be very low. </p> </section> <section id="CD010341-sec-0101"> <h5 class="title">Locoregional control</h5> <p>There was no evidence of a difference in locoregional control between groups receiving a TKI (either erlotinib or lapatinib) plus CRT and groups receiving CRT alone in the two phase II trials that evaluated this comparison (<a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; 271 participants, 66% OP tumours, 7% OC tumours) (HR 0.89; 95% CI 0.53 to 1.49; P value = 0.65) (<a href="./references#CD010341-fig-0008" title="">Analysis 2.2</a>). We assessed the quality of this evidence to be very low. </p> </section> <section id="CD010341-sec-0102"> <h5 class="title">Disease‐free survival</h5> <p>One study of participants with OC tumours (<a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>; 60 participants, 100% OC tumours) reported no evidence of a difference in DFS between participants treated with gefitinib plus RT and participants who received RT alone (HR 1.51; 95% CI 0.61 to 3.71; P values = 0.37) (<a href="./references#CD010341-fig-0009" title="">Analysis 2.3</a>). We assessed the quality of this evidence to be very low. </p> </section> <section id="CD010341-sec-0103"> <h5 class="title">Progression‐free survival</h5> <p>There was no evidence of a difference in PFS between groups receiving a TKI (either erlotinib or lapatinib) plus CRT and participants receiving CRT alone in the two phase II trials that evaluated this comparison (<a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; 271 participants, 66% OP tumours, 7.5% OC tumours) (HR 0.80; 95% CI 0.51 to 1.28; P value = 0.36) (<a href="./references#CD010341-fig-0010" title="">Analysis 2.4</a>). We assessed the quality of this evidence to be very low. </p> </section> <section id="CD010341-sec-0104"> <h5 class="title">Adverse effects</h5> <p>The most commonly reported adverse effects from each study are listed below and in <a href="#CD010341-tbl-0007">Table 4</a>. </p> <div class="table" id="CD010341-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse event outcomes: comparison 2: tyrosine kinase inhibitors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (MH, 95% CI, P value)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity (P value; I<sup>2</sup>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>2.5 Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.94 to 1.11) (fixed effect) P value = 0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.44; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22 (0.96 to 1.56) (fixed effect) P value = 0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.53; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>2.6 Skin toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value &lt; 0.00001; I<sup>2</sup> = 95.5%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (gefitinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.82 to 1.28) (fixed effect) P value = 0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value = 0.42; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (lapatinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.02 (1.23 to 3.32) P value = 0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (erlotinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.57 (3.60 to 12.00) P value &lt; 0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25 (0.54 to 2.88) (random effects) P value = 0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.09; I<sup>2</sup> = 54% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>2.7 Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value = 0.007; I<sup>2</sup> = 86.2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (gefitinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.98 to 1.11) P value = 0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (lapatinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.53 (2.18 to 110.55) P value = 0.006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.83 to 1.49) (fixed effect) P value = 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.53; I<sup>2</sup> = 0% </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; MH: Mantel‐Haenszel.</p> </div> </div> <section id="CD010341-sec-0105"> <h6 class="title">Mucositis</h6> <section id="CD010341-sec-0106"> <p><b>All grades</b></p> <p>Two studies (17% (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>); 286 participants: fixed‐effect analysis) compared the addition of a TKI to standard therapy with standard therapy alone (placebo used in one study). There was no evidence to refute or support an increase or reduction in mucositis occurrence across all grades for participants treated with TKI (RR 1.03; 95% CI 0.94 to 1.11; P value = 0.55). There was no evidence of heterogeneity (P value = 0.44; I<sup>2</sup> = 0%). </p> </section> <section id="CD010341-sec-0107"> <p><b>Grades 3 or higher</b></p> <p>Two studies (17% (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>); 286 participants: fixed‐effect analysis) compared the addition of a TKI to standard therapy with standard therapy alone (placebo used in one study). There was no evidence to refute or support an increase or reduction in mucositis occurrence at grades 3 or higher for participants treated with TKI (RR 1.22; 95% CI 0.96 to 1.56; P value = 0.10). There was no evidence of heterogeneity (P value = 0.53; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010341-sec-0108"> <h6 class="title">Skin toxicity</h6> <section id="CD010341-sec-0109"> <p><b>All grades</b></p> <p>Four studies (33% (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>); 544 participants: random‐effects analysis) compared the addition of a TKI to standard therapy with standard therapy alone (placebo used in two studies). There were significant differences between the three (gefitinib, lapatinib, erlotinib) subgroups (P value &lt; 0.00001; I<sup>2</sup> = 95.5%). </p> <p>In the erlotinib subgroup, there was evidence of an increase in skin toxicity across all grades (RR 6.57; 95% CI 3.60 to 12.00; P value &lt; 0.00001). There was evidence of an increase in skin toxicity across all grades in the lapatinib subgroup(RR 2.02; 95% CI 1.23 to 3.32; P value = 0.005). There was no evidence to refute or support an increase or reduction in skin toxicity across all grades in the gefitinib subgroup (RR 1.03; 95% CI 0.82 to 1.28; P value = 0.82), and there was no evidence of heterogeneity (P value = 0.42; I<sup>2</sup> = 0%). </p> </section> <section id="CD010341-sec-0110"> <p><b>Grades 3 or higher</b></p> <p>Four studies (33% (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>); 544 participants: random‐effects analysis) compared the addition of a TKI to standard therapy with standard therapy alone (placebo used in two studies). There was no evidence to refute or support an increase or reduction in skin toxicity at grades 3 or higher for participants treated with TKI (RR 1.25; 95% CI 0.54 to 2.88; P value = 0.61). There was a moderate amount of heterogeneity (P value = 0.09; I<sup>2</sup> = 54%), as explained by the all grades data above. </p> </section> </section> <section id="CD010341-sec-0111"> <h6 class="title">Gastrointestinal complaints</h6> <section id="CD010341-sec-0112"> <p><b>All grades</b></p> <p>Two studies (17% (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>); 293 participants: fixed‐effect analysis) compared the addition of a TKI to standard therapy with standard therapy alone (placebo used in two studies). There was a significant difference between the two (gefitinib, lapatinib) subgroups (P value = 0.007; I<sup>2</sup> = 86.2%). </p> <p>There was evidence of an increase in gastrointestinal complaints across all grades in the lapatinib subgroup (RR 15.53; 95% CI 2.18 to 110.55; P value = 0.006). There was no evidence to refute or support an increase or reduction in gastrointestinal complaints across all grades in the gefitinib subgroup (RR 1.04; (95% CI 0.98 to 1.11; P value = 0.18). </p> </section> <section id="CD010341-sec-0113"> <p><b>Grades 3 or higher</b></p> <p>Three studies (25% (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>); 484 participants: fixed‐effect analysis) compared the addition of a TKI to standard therapy with standard therapy alone (placebo used in two studies). There was no evidence to refute or support an increase or reduction in gastrointestinal complaints at grades 3 or higher for people treated with TKI (RR 1.11; 95% CI 0.83 to 1.49; P value = 0.47). There was no evidence of heterogeneity (P value = 0.53; I<sup>2</sup> = 0%). </p> </section> </section> </section> </section> <section id="CD010341-sec-0114"> <h4 class="title">Comparison 3: Immunotherapy plus standard therapy versus standard therapy alone</h4> <p>Three trials evaluated the effect of administering immunotherapies in addition to other standard treatments (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>). In these three trials, 57% of participants had OC tumours while 36% had OP tumours. Two trials compared the effect rIL‐2 (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>). <a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a> evaluated rIL‐2 concomitant with surgery in a trial of 201 participants. <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a> compared neoadjuvant chemotherapy with the same neoadjuvant chemotherapy regimen plus two five‐day courses of rIL‐2 administered during each cycle. The paper reported an interim analysis based on the first 33 participants randomised to treatment. Both trials were at unclear risk of bias; neither use a placebo control and reporting was poor in both trial reports. </p> <p>One study evaluated BCG‐CWP in combination with standard therapy (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>). In a small group of 24 participants with OP cancers, half were randomised to pretreatment with BCG‐CWP followed by surgery, while half received surgery alone. This study was at unclear risk of bias and only reported one of our primary outcome measures. </p> <section id="CD010341-sec-0115"> <h5 class="title">Overall survival</h5> <p>There was a benefit in overall survival favouring the group treated with rIL‐2 plus surgery in one small trial (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; 201 participants, 62% OC tumours, 38% OP tumours) (HR 0.52; 95% CI 0.31 to 0.87; P value = 0.01) (<a href="./references#CD010341-fig-0011" title="">Analysis 3.1</a>). </p> <p>The number of participants in the study that reported overall survival (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; 24 participants, 75% OC tumours) was too low to be able to calculate an HR from the survival curve, and there was no statistically significant difference between the pretreatment group and control with regard to the numbers of participants alive after three years (<a href="#CD010341-tbl-0008">Table 5</a>). We assessed the quality of this evidence to be very low. </p> <div class="table" id="CD010341-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Outcome data from Bier 1981</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BCG‐cell wall preparation + surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Surgery alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall survival (3 years)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrence (3 years)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/10</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCG: Bacillus Calmette‐Guérin.</p> </div> </div> </section> <section id="CD010341-sec-0116"> <h5 class="title">Locoregional control</h5> <p>The results from the interim analysis of one small trial (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; 30 participants, 12% OC tumours, 45% OP tumours) gave insufficient evidence to determine a difference in locoregional control (neither partial nor complete response) between the neoadjuvant chemotherapy plus rIL‐2 group and the neoadjuvant chemotherapy alone group (<a href="#CD010341-tbl-0009">Table 6</a>). The authors of this paper stated that, "it is highly improbable that a clinically significant difference between the two treatment groups will be observed even if the calculated patient sample size is achieved". </p> <div class="table" id="CD010341-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcome data from Mantovani 1998</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neoadjuvant chemotherapy (n = 17)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neoadjuvant chemotherapy + rIL‐2 (n = 16)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Locoregional control</p> <p>Complete response</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Locoregional control</p> <p>Partial response</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/13</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>rIL‐2: recombinant interleukin.</p> </div> </div> </section> <section id="CD010341-sec-0117"> <h5 class="title">Disease‐free survival</h5> <p>There was no evidence of a difference in disease‐free survival between participants treated with rIL‐2 plus surgery compared with surgery alone (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>; one study; 201 participants, 62% OC tumours, 38% OP tumours). Results showed a possible benefit favouring rIL‐2 plus surgery over surgery alone, but this did not attain statistical significance (HR 0.66; 95% CI 0.43 to 1.02; P value = 0.06) (<a href="./references#CD010341-fig-0012" title="">Analysis 3.2</a>). We assessed the quality of this evidence to be very low. </p> </section> <section id="CD010341-sec-0118"> <h5 class="title">Adverse effects</h5> <p>The most commonly reported adverse effects from each study are listed below and in <a href="#CD010341-tbl-0010">Table 7</a>. </p> <div class="table" id="CD010341-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse event outcomes: comparison 3: immunotherapies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk ratio (MH, 95% CI, P value)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Heterogeneity (P value; I<sup>2</sup>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>3.3 Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.90 to 1.70) P value = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.40 (0.15 to 77.34) P value = 0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>3.4 Stomatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.47 (0.75 to 2.90) P value = 0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71 (0.33 to 8.83) P value = 0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>3.5 Leukopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.22 to 1.50) P value = 0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.04 to 3.26) P value = 0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.6 Increased temperature</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.13 to 3.30) P value = 0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.7 Moderate‐severe chills</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.00 (0.67 to 179.29) P value = 0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.8 Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.27 to 94.34) P value = 0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; MH: Mantel‐Haenszel.</p> </div> </div> <section id="CD010341-sec-0119"> <h6 class="title">Nausea/vomiting</h6> <section id="CD010341-sec-0120"> <p><b>All grades</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); 30 participants) compared rIL‐2 plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in nausea/vomiting across all grades for participants treated with rIL‐2 (RR 1.24; 95% CI 0.90 to 1.70; P value = 0.19). </p> </section> <section id="CD010341-sec-0121"> <p><b>Grades 3 or higher</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); 30 participants) compared rIL‐2 plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in nausea/vomiting at grades 3 or higher for participants treated with rIL‐2 (RR 3.40; 95% CI 0.15 to 77.34; P value = 0.44). </p> </section> </section> <section id="CD010341-sec-0122"> <h6 class="title">Stomatitis</h6> <section id="CD010341-sec-0123"> <p><b>All grades</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); 30 participants) compared rIL‐2 plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in stomatitis across all grades for participants treated with rIL‐2 (RR 1.47; 95% CI 0.75 to 2.90; P value = 0.27). </p> </section> <section id="CD010341-sec-0124"> <p><b>Grades 3 or higher</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); 30 participants) compared rIL‐2 plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in stomatitis at grades 3 or higher for participants treated with rIL‐2 (RR 1.71; 95% CI 0.33 to 8.83; P value = 0.52). </p> </section> </section> <section id="CD010341-sec-0125"> <h6 class="title">Leukopenia</h6> <section id="CD010341-sec-0126"> <p><b>All grades</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); 30 participants) compared rIL‐2 plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in leukopenia occurrence across all grades for participants treated with rIL‐2 (RR 0.57; 95% CI 0.22 to 1.50; P value = 0.25). </p> </section> <section id="CD010341-sec-0127"> <p><b>Grades 3 or higher</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>); 30 participants) compared rIL‐2 plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in leukopenia occurrence at grades 3 or higher for participants treated with rIL‐2 (RR 0.38; 95% CI 0.04 to 3.26; P value = 0.38). </p> </section> </section> <section id="CD010341-sec-0128"> <h6 class="title">Increased temperature</h6> <section id="CD010341-sec-0129"> <p><b>All grades</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>); 24 participants) compared immunotherapy plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in increased temperature across all grades for participants treated with immunotherapy (RR 0.67; 95% CI 0.13 to 3.30; P value = 0.62). </p> </section> </section> <section id="CD010341-sec-0130"> <h6 class="title">Moderate‐severe chills</h6> <section id="CD010341-sec-0131"> <p><b>All grades</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>); 24 participants) compared immunotherapy plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in moderate‐severe chills across all grades for participants treated with immunotherapy (RR 11.00; 95% CI 0.67 to 179.29; P value = 0.09). </p> </section> </section> <section id="CD010341-sec-0132"> <h6 class="title">Gastrointestinal complaints</h6> <section id="CD010341-sec-0133"> <p><b>All grades</b></p> <p>One study (8% (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>); 24 participants) compared immunotherapy plus standard therapy with standard therapy alone (without placebo). There was no evidence to refute or support an increase or reduction in gastrointestinal complaints across all grades for participants treated with immunotherapy (RR 5.00; 95% CI 0.27 to 94.34; P value = 0.28). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010341-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010341-sec-0134"></div> <section id="CD010341-sec-0135"> <h3 class="title" id="CD010341-sec-0135">Summary of main results</h3> <p>Twelve studies met the inclusion criteria for this review. For each comparison and outcome considered in the review, we assessed the quality of the body of evidence using the GRADE method, which takes into account the risk of bias of the included studies, directness of the evidence, consistency of the results (heterogeneity), precision of the effect estimates, and risk of publication bias (<a href="./references#CD010341-bbs2-0104" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">GRADE 2004</a>). We have presented our results and quality assessment in 'Summary of findings' tables for each type of targeted therapy (<a href="./full#CD010341-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010341-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010341-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD010341-sec-0136"> <h4 class="title">Monoclonal antibodies</h4> <p>There was evidence to suggest that there may be an 18% reduction in deaths in the participants treated with EGFR mAb therapies in addition to standard therapies. The body of evidence for this outcome is moderate quality. Sixty‐seven per cent of these participants had OP tumours and 2% had OC tumours. There was insufficient evidence to determine whether there was an impact on our primary outcomes in subgroups that compared mAbs plus RT with RT alone and mAbs plus CRT with CRT alone. However, there were very few studies in this analysis, and it is important to re‐visit the differences between these clinically important subgroups in future review updates. </p> <p>There was moderate quality evidence from this large study that EGFR mAb therapy, namely cetuximab, in combination with RT may decrease locoregional failures by 32%. This was based on a single study and our confidence in these findings would be further strengthened if they were independently replicated. </p> <p>The body of evidence for progression‐free survival showed high heterogeneity caused by subgroup differences and imprecision. As a result of the heterogeneity, we were unable to pool data across subgroups. The subgroup comparing mAb plus RT with RT alone showed some evidence that adding EGFR mAb therapy to RT results in a 30% reduction in the number of participants whose disease progresses. However, this estimate was based on a single study at unclear risk of bias. The subgroup comparing mAb plus CRT with CRT alone also contained only one study at high risk of bias, meaning that there was insufficient evidence to determine whether adding EGFR mAb therapy to CRT results in a change in progression‐free survival. </p> <p>There was evidence that adding cetuximab to standard therapy may result in increased skin toxicity and rash, but insufficient evidence to determine whether there was a difference in the case of nimotuzumab. There was insufficient evidence to determine a difference for other adverse effects for either of the EGFR mAb therapies. There was no evidence that adding EGFR mAb to standard therapy results in a difference in quality of life. </p> </section> <section id="CD010341-sec-0137"> <h4 class="title">Tyrosine kinase inhibitors</h4> <p>There was insufficient evidence to determine whether TKIs added to standard therapy impacts on overall survival, progression‐free survival or locoregional control. The quality of the body of evidence for these findings was very low for all of these outcomes. </p> <p>There was evidence that adding certain TKIs to standard therapy may result in increased gastrointestinal complaints (lapatinib) and rash (erlotinib, lapatinib). There was no evidence of a difference for other adverse effects. </p> </section> <section id="CD010341-sec-0138"> <h4 class="title">Interleukins</h4> <p>There was very low quality evidence from one study with a small sample size that the addition of rIL‐2 to surgery increases overall survival. There was limited very low quality evidence suggesting a possible increase in disease‐free survival resulting from the addition of rIL‐2 to surgery. There was insufficient evidence to determine whether adding interleukins to standard therapy results in a difference in adverse effects. </p> </section> </section> <section id="CD010341-sec-0139"> <h3 class="title" id="CD010341-sec-0139">Overall completeness and applicability of evidence</h3> <p>There is only a small body of evidence that we were able to include in this review, which limits the conclusions we can draw. We included 12 trials in the review, but of those from which we could extract or calculate HRs, we identified only three trials that evaluated mAb (all against EGFR) (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>), three that evaluated TKIs (<a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0009" title="HayesDN , RaezLE , SharmaAK , PapagikosMA , YunusF , ParvathaneniU , et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results. Journal of Clinical Oncology2010;28 Suppl:Abstract 5580. MartinsRG , ParvathaneniU , BaumanJE , SharmaAK , RaezLE , PapagikosMA , et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of Clinical Oncology2013; Vol. 31, issue 11:1415‐21. ">Martins 2013</a>; <a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>), and one that evaluated interleukins (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>). Of the remaining five trials (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>; <a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>), three did not present data in a format that allowed us to calculate HRs or draw firm conclusions from the data (<a href="./references#CD010341-bbs2-0002" title="BierJ , RappHJ , BorsosT . Randomized clinical study on intratumoral BCG‐cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region. Cancer Immunology, Immunotherapy1981; Vol. 12, issue 1:71‐9. ">Bier 1981</a>; <a href="./references#CD010341-bbs2-0007" title="KohY , LeeKW , KimSB , ParkKH , ShinSW , KangJH , et al. A randomised multicentre open phase 2 study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable locally advanced head and neck squamous cell cancer. Journal of Clinical Oncology2013;31:Abstract 6069. ">Koh 2013</a>; <a href="./references#CD010341-bbs2-0008" title="MantovaniG , GebbiaV , AiroldiM , BummaC , ContuP , BianchiA , et al. Neo‐adjuvant chemo‐(immuno‐)therapy of advanced squamous‐cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5‐fluorouracil (5‐FU) with cisplatin + 5‐FU + recombinant interleukin 2. Cancer Immunology, Immunotherapy1998; Vol. 47, issue 3:149‐56. ">Mantovani 1998</a>). One trial had major inconsistencies in the HRs presented in the study report, such that we could not make meaningful use of the data (<a href="./references#CD010341-bbs2-0010" title="BabuKG , ViswanathL , ReddyBK , ShenoyK , ShenoyA , NaveenT , et al. An open‐label, randomized, study of h‐R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four‐year survival results from a phase IIb study. Journal of Clinical Oncology2010;28 Suppl:Abstract 5530. KrishnamurthyreddyB , VidyasagarMS , KoteshwarR , ShenoyA , ViswanathL , ThimmaiahN , et al. A phase IIb 4‐arm open‐label randomized study to assess the safety and efficacy of h‐R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. Journal of Clinical Oncology2009;27 Suppl:Abstract 6041. ReddyBK , LokeshV , VidyasagarMS , ShenoyK , BabuKG , ShenoyA , et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open‐label, phase IIb, 5‐year study in Indian patients. Oral Oncology2014;50(5):498‐505. ViswanathL , ThimmaiahL , BayyagariK , ShenoyK , AshokS , GovindaB , et al. Randomized study to assess safety &amp; efficacy of H‐R3 monoclonal antibody against EGF receptor in combination with chemo‐radiation therapy advanced (stage III or IVA) head and neck cancer. Annals of Oncology2009;20:iii45. ">Reddy 2014</a>). We were unable to obtain outcome data for the comparisons of interest in the study by <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>, as there was no reply to our email enquiry requesting outcome data by randomised group. </p> <p>There were some indications that there may be differences in the efficacy of targeted therapies, namely mAb, when administered concomitantly with CRT versus RT. However, with such a limited number of studies we were unable to draw firm conclusions about this. These are clinically important subgroups and additional high quality studies evaluating mAb in combination with these two different standard therapies will enable us to detect such differences, if they exist, in future updates of this review. </p> <p>There also may be differences in the efficacy of different targeted therapies within each category (e.g. differences in efficacy between cetuximab and nimotuzumab) creating heterogeneity in the pooled results. More high quality studies of each targeted therapy would mean that we could assess this. </p> <p>The studies that we were able to include in this review only evaluated mAb against EGFR and we were thus only able to draw concussions about mAb against this particular target. High quality trials evaluating mAb against other targets are required. </p> <p>In accordance with our original protocol, we have only included studies in which the targeted therapy or immunotherapy was administered concomitantly with the standard therapy. However, when screening the results of our search, we identified several studies that used targeted therapies as neoadjuvant treatments. We consider that it is important to evaluate the efficacy of these neoadjuvant targeted therapy trials in treating oral and OP cancers, and propose that these trials are included in the next update of this review. </p> <p>There are an increasing number of trials in progress that compare concomitant targeted therapy and RT with concomitant CRT, CRT being the current evidence‐based standard of care. Comparing these two specific treatment regimens falls outside of the remit of this review in its current form. However, we will evaluate this treatment comparison in the update of this review. </p> <p>The studies that we were able to include evaluating non‐specific immunotherapies were limited (only BCG‐CWP and IL‐2 were evaluated), low quality and older than the other trials included in this review. However, there are an increasing number of trials in progress examining the efficacy of immunotherapy through 'checkpoint' inhibition by mAb (e.g. PD‐1 or PD‐L1 inhibitors) in multiple malignancies including head and neck cancers. These will inform future updates of this review. </p> <p>As with another review in this suite of reviews on interventions for oral and OP cancer (<a href="./references#CD010341-bbs2-0102" title="FurnessS , GlennyAM , WorthingtonHV , PavittS , OliverR , ClarksonJE , et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD006386.pub3] ">Furness 2011</a>), we found that the majority of trials specified squamous cell carcinoma of the head and neck in the inclusion criteria, rather than oral and OP cancer. Only one of the included trials specifically recruited participants with OC cancer (<a href="./references#CD010341-bbs2-0012" title="SinghKR , DixitAK , PrashadSN , SaxenaT , ShahooDP , SharmaD . A randomized trial comparing radiotherapy alone versus radiotherapy with geftinib in locally advance oral cavity cancer. Clinical Cancer Investigation Journal2013;2:29‐33. ">Singh 2013</a>), and another trial included only oral and OP cancer (<a href="./references#CD010341-bbs2-0004" title="DeStefaniA , ForniG , RagonaR , CavalloG , BussiM , UsaiA , et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer2002; Vol. 95, issue 1:90‐7. ">De Stefani 2002</a>). The authors of one trial provided separate data for tumours with different primary distributions (<a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>). In the remaining nine trials included in this systematic review, at least 50% of participants had either OC or OP cancer. We have included these trials because we believe that they contribute important information concerning the effectiveness of targeted therapies and immunotherapies in OC and OP cancers, in the absence of separate data in the research literature. However, we acknowledge that trials on the two specific cancer sites, or combined trials where the data are reported separately by primary tumour site, would yield much better information to guide clinical practice in these two conditions that have important differences in aetiology, presentation and management. We look forward to trials on OC or OP cancer alone being available for inclusion in future updates of this review. </p> </section> <section id="CD010341-sec-0140"> <h3 class="title" id="CD010341-sec-0140">Quality of the evidence</h3> <p>The quality of the evidence included in this review limits the confidence with which we can draw conclusions about the efficacy of targeted therapies in treating OC and OP cancers. None of the studies included in this review were at low risk of bias: we assessed seven at unclear risk of bias, and five at high risk of bias. </p> <p>We considered these risk of bias issues in conjunction with the fact that some of the studies in each comparison/outcome were single studies, were imprecise, had limited applicability in their findings, or a combination of these three factors. This resulted in our rating the evidence as very low quality for all interventions and outcomes, other than EGFR mAbs for overall survival and locoregional control, which we rated as moderate quality evidence. </p> <p>Only three of the trials included in this systematic review used blinding of participants (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>; <a href="./references#CD010341-bbs2-0011" title="RodriguezMO , RiveroTC , BahiRDC , MuchuliCR , BilbaoMA , VinagerasEN , et al. Nimotuzumab plus radiotherapy for unresectable squamous‐cell carcinoma of the head and neck. Cancer Biology and Therapy2010; Vol. 9, issue 5:343‐9. ">Rodriguez 2010</a>), and four used blinding of outcome assessors (<a href="./references#CD010341-bbs2-0001" title="AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2011;29:Abstract 5500. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III‐IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology2014;32(27):2940‐50. AngKK , ZhangQE , RosenthalDI , Nguyen‐TanP , ShermanEJ , WeberRS , et al. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clinical Advances in Hematology &amp; Oncology2007;5(2):79‐81. [PUBMED: 17344795] ">Ang 2014</a>; <a href="./references#CD010341-bbs2-0003" title="ArmstrongJG . Cetuximab plus radiotherapy for head and neck cancer (letters + author reply). New England Journal of Medicine2006;354(20):2187. BonnerJA , GiraltJ , HarariPM , CohenR , JonesC , SurRK , et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology2004; Vol. 22, issue 14S:Abstract 5507. BonnerJA , GiraltJ , HarariPM , JonesC , CohenR , SurRK , et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2004;60(1 Suppl):Abstract 31. BonnerJA , HarariPM , GiraltJ , AzarniaN , ShinDM , CohenRB , et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. New England Journal of Medicine2006; Vol. 354, issue 6:567‐78. BonnerJA , HarariPM , GiraltJ , CohenRB , BaselgaJM , SpencerSA , et al. EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2006; Vol. 24, issue 18S:5510. BonnerJA , HarariPM , GiraltJ , CohenRB , JonesCU , SurRK , et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncology2010; Vol. 11, issue 1:21‐8. CurranD , GiraltJ , HarariPM , AngKK , CohenRB , KiesMS , et al. Quality of life in head and neck cancer patients after treatment with high‐dose radiotherapy alone or in combination with cetuximab. [Erratum appears in Journal of Clinical Oncology 2007 25(24):3790]. Journal of Clinical Oncology2007; Vol. 25, issue 16:2191‐7. FurnessS [pers comm] . Bonner data.xls. Email to: JA Bonner 6 August 2013. HarariPM , GiraltJL , AzarniaN , MolloyP , CohenR , RabenD , et al. Results of an international phase III trial of radiation +/‐ cetuximab (Erbitux) in patients with locoregionally advanced H&amp;N cancer. Proceedings of the 6th International Conference on Head and Neck Cancer; 2004 Aug 7‐11; Washington, DC. 2004:Abstract s087. MellLK , DignamJJ , SalamaJK , HarafDJ , VokesEE , WeichselbaumRR . Does cetuximab improve control of advanced head and neck cancer? A second look at the randomized trial by Bonner, et al. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):Abstract 2387. MellLK , WeichselbaumRR . More on cetuximab in head and neck cancer. New England Journal of Medicine2007; Vol. 357, issue 21:2201‐2; author reply 2202‐3. StengerM , KnopfKB . Targeted therapy combined with radiotherapy for squamous cell head and neck cancer. Community Oncology2006; Vol. 3, issue 12:745‐8. ">Bonner 2006</a>; <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>; <a href="./references#CD010341-bbs2-0006" title="HarringtonK , BerrierA , RobinsonM , RemenarE , HoussetM , deMendozaFH , et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus‐negative disease. European Journal of Cancer2013; Vol. 49, issue 7:1609‐18. [1879‐0852: (Electronic)] HarringtonKJ , BerrierA , RobinsonM , RemenarE , HoussetM , Hurtado De MendozaF , et al. Phase II study of oral lapatinib, a dual‐tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology2010;28 Suppl:Abstract 5505. ">Harrington 2013</a>). We recognise that blinding is difficult to maintain in such trials of targeted therapies and immunotherapies. There are ethical issues surrounding the blinding of participants or their clinicians to the treatment being administered, as different agents and regimens require different monitoring of participants for both benefits and harms. Adverse effects of targeted therapies, such as the characteristic skin rash that results in a large proportion of participants who have received erlotinib (<a href="./references#CD010341-bbs2-0112" title="IyerR , BharthuarA . A review of erlotinib ‐ an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opinion on Pharmacotherapy2010;11(2):311‐20. ">Iyer 2010</a>), may also make blinding impossible. However, adopting clear outcome criteria and using a panel of experts blinded to intervention to review outcomes would be a pragmatic step to reduce the risk of bias for the more subjective outcomes, such as adverse effects and quality of life. </p> <p>As the methodology of clinical trials has improved over time, the criteria used to define progression‐ and disease‐free survival have also become more detailed and standardised. Therefore, a limitation of our review is that the criteria used to define DFS and PFS in the studies included in our review were not the same (and perhaps not expected to be same) given that these studies were conducted at different times since the mid‐1980s. </p> <p>There is a possibility of publication bias in this review. See <a href="#CD010341-sec-0141">Potential biases in the review process</a>. </p> </section> <section id="CD010341-sec-0141"> <h3 class="title" id="CD010341-sec-0141">Potential biases in the review process</h3> <p>We have included 12 trials in this review but we expect that there are other trials that have been conducted that we have not been able to identify. Many of the trials of targeted or immunotherapies for OC or OP cancers are conducted by pharmaceutical companies, and the results of phase I and II trials in particular are seldom available for inclusion in systematic reviews due to the commercial sensitivities involved. Two studies that met the inclusion criteria but for which we were unable to obtain the original data were <a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a> and <a href="./references#CD010341-bbs2-0076" title="AstraZeneca . The IRESSA novel head and neck chemotherapy evaluation study. Clinicaltrials.gov/ct2/show/NCT00255476(accessed February 2015). ">NCT00255476</a>. </p> </section> <section id="CD010341-sec-0142"> <h3 class="title" id="CD010341-sec-0142">Agreements and disagreements with other studies or reviews</h3> <p>We have not identified any other systematic reviews of targeted or immunotherapy for OC or OP cancers. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010341-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Review flow diagram" data-id="CD010341-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010341-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010341-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Monoclonal antibodies (mAb), Outcome 1 Overall survival (5 years)." data-id="CD010341-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Monoclonal antibodies (mAb), Outcome 1 Overall survival (5 years).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Monoclonal antibodies (mAb), Outcome 2 Locoregional control." data-id="CD010341-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Monoclonal antibodies (mAb), Outcome 2 Locoregional control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Monoclonal antibodies (mAb), Outcome 3 Progression‐free survival." data-id="CD010341-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Monoclonal antibodies (mAb), Outcome 3 Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 1 Overall survival." data-id="CD010341-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 2 Locoregional control." data-id="CD010341-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 2 Locoregional control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 3 Disease‐free survival." data-id="CD010341-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 3 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 4 Progression‐free survival." data-id="CD010341-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Tyrosine kinase inhibitors (TKI), Outcome 4 Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Immunotherapy, Outcome 1 Overall survival." data-id="CD010341-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Immunotherapy, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010341-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/urn:x-wiley:14651858:media:CD010341:CD010341-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_t/tCD010341-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Immunotherapy, Outcome 2 Disease‐free survival." data-id="CD010341-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Immunotherapy, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/media/CDSR/CD010341/image_n/nCD010341-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010341-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity or oropharyngeal cancers</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br/> <b>Settings:</b> secondary care<br/> <b>Intervention:</b> EGFR mAb (either cetuximab or nimotuzumab + either RT or CRT) </p> <p><b>Comparison:</b> RT or CRT alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> <p><b> mAb</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.82</b> <br/> (0.69 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1421<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was an 18% reduction in death (during the follow‐up period) in the participants treated with EGFR mAb therapies in addition to standard therapies </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000 (113 to 156)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>347 per 1000 (301 to 396)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>577 per 1000 (515 to 639)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Locoregional control</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.68</b> <br/> (0.52 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>424<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was a 32% reduction in recurrence of cancer (during the follow‐up period) in the participants treated with EGFR mAb therapies (cetuximab) in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>112 per 1000 (87 to 144)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>297 per 1000 (237 to 370)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>510 per 1000 (421 to 607)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>We formed 2 subgroups: mAb therapy + RT versus RT alone and mAb therapy + CRT versus CRT alone. There was a significant difference between these subgroups (P value = 0.008; I<sup>2</sup> = 86%) and as a result we were unable to pool the data. The subgroup comparing mAb therapy + RT versus RT alone reported a 30% reduction in the number of people whose disease progresses if treated with EGFR mAb in addition to RT (HR 0.70; 95% CI 0.54 to 0.91; P value = 0.006). However, the subgroup comparing mAb therapy + CRT versus CRT alone reported no evidence of a difference in progression‐free survival (HR 1.08; 95% CI 0.89 to 1.32; P value = 0.76) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>A subgroup estimate shows evidence of an increase in skin toxicity/acneiform rash (all grades of adverse effects: RR 6.56, 95% CI 5.35 to 8.03; 1311 participants, 2 studies; adverse effects grades ≥ 3: RR 17.72, 95% CI 8.33 to 37.73; 1403 participants, 3 studies) in people treated with cetuximab in addition to standard therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>EGFR:</b> epidermal growth factor receptor; <b>mAb:</b> monoclonal antibody; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5‐year survival data (<a href="./references#CD010341-bbs2-0127" title="PulteD , BrennerH . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist2010;15(9):994‐1001. ">Pulte 2010</a>). </p> <p><sup>1</sup> Downgraded once for reporting bias (potential publication bias and poor reporting of EGFR and biopsy data in one study).<br/> <sup>2</sup> Downgraded once due to this being a single study at unclear risk of performance bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity or oropharyngeal cancers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010341-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tyrosine kinase inhibitors plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tyrosine kinase inhibitors in addition to standard treatments for people with oral cavity and oropharyngeal cancers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br/> <b>Settings:</b> secondary care<br/> <b>Intervention:</b> tyrosine kinase inhibitors (erlotinib, gefitinib or lapatinib) + standard therapy (either RT or CRT) </p> <p><b>Comparison:</b> standard therapy (either RT or CRT alone) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> <p><b> Tyrosine kinase inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.99</b> <br/> (0.62 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in participant survival in people treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>159 per 1000 (102 to 239)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>402 per 1000 (275 to 557)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>646 per 1000 (478 to 808)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Locoregional control</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.89</b> <br/> (0.53 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in locoregional control in people treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>144 per 1000 (88 to 229)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>370 per 1000 (241 to 539)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>607 per 1000 (429 to 791)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Disease‐free Survival</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 1.51</b> <br/> (0.61 to 3.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in the length of time that participants survived without signs or symptoms of oral cavity cancer when treated with tyrosine kinase inhibitors (gefitinib) in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>231 per 1000 (101 to 476)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>543 per 1000 (271 to 854)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>795 per 1000 (473 to 980)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Progression‐free Survival</b> <br/> Follow‐up: 40‐60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.8</b> <br/> (0.51 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was no evidence of a difference in the length of time that participants stayed alive with stable disease when treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>130 per 1000 (85 to 200)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>340 per 1000 (233 to 486)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>568 per 1000 (415 to 739)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>A subgroup estimate showed evidence of an increase in gastrointestinal complaints (all grades of adverse effects: RR 15.53, 95% CI 2.18 to 110.55; 67 participants, 1 study) in people treated with lapatinib in addition to standard therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5‐year survival data (<a href="./references#CD010341-bbs2-0127" title="PulteD , BrennerH . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist2010;15(9):994‐1001. ">Pulte 2010</a>). </p> <p><sup>1</sup> Downgraded once due reporting bias (data from a large study (<a href="./references#CD010341-bbs2-0005" title="GregoireV , HamoirM , ChenC , KaneM , KaweckiA , JulkaPK , et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double‐blind, placebo‐controlled study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology2011; Vol. 100, issue 1:62‐9. RogersS , CollierR , ClarkE , TanayM , HickeyJ , BoxC , et al. Inhance (Iressa (TM) novel head and neck chemotherapy evaluation) randomised phase II trial: clinical findings and associated translational research into EGFR‐related biomarkers in tumour and skin biopsies. EJC Supplements2009; Vol. 7, issue 4:28. ">Gregoire 2011</a>) was not available). </p> <p><sup>2</sup> Downgraded once due to imprecision </p> <p><sup>3</sup> Downgraded once due to unclear risk of bias across multiple domains. </p> <p><sup>4</sup> Downgraded once for applicability ‐ only participants receiving RT as a standard therapy were included in this subgroup (no CRT). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tyrosine kinase inhibitors plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010341-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Immunotherapy plus standard therapy versus standard therapy alone for the treatment of people with oral and oropharyngeal cancers</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Recombinant Interleukin (rIL‐2) in addition to surgery for the treatment of people with oral and oropharyngeal cancers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br/> <b>Settings:</b> secondary care<br/> <b>Intervention:</b> recombinant Interleukin (rIL‐2) + standard therapy (surgery) </p> <p><b>Comparison:</b> standard therapy (surgery) alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> <p><b> rIL‐2</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.52</b> </p> <p>(0.31 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>201<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There was an 48% reduction in death in the groups treated with rIL‐2 in addition to standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1000<br/> (53 to 141) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>237 per 1000</p> <p>(149 to 363)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>421 per 1000</p> <p>(278 to 599)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Disease‐free survival</b> <br/> Follow‐up: 24‐70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low‐risk population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.66</b> <br/> (0.43 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>201<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>There is no evidence of a difference in the length of time that participants survived without signs or symptoms of cancer when treated with rIL‐2 in addition to standard therapies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>109 per 1000</p> <p>(72 to 163)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>290 per 1000</p> <p>(200 to 411)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population*</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>650 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>500 per 1000</p> <p>(363 to 657)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>There was no evidence of an increase or reduction of nausea/vomiting, stomatitis or leukopenia in participants treated with rIL‐2 in addition to standard therapy (1 study, 30 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5‐year survival data (<a href="./references#CD010341-bbs2-0127" title="PulteD , BrennerH . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist2010;15(9):994‐1001. ">Pulte 2010</a>) </p> <p><sup>1</sup> Downgraded twice due to high/unclear risk of bias across domains.<br/> <sup>2</sup> Downgraded once due to this being a single study and due to applicability (only participants receiving surgery as a standard therapy were included in this subgroup (no RT/CRT). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Immunotherapy plus standard therapy versus standard therapy alone for the treatment of people with oral and oropharyngeal cancers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of inclusion and exclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Inclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exclusion criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Location of cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with primary cancer of the oral cavity (ICD‐O: C01‐06) or oropharynx (ICD‐O: C09‐10 ‐ includes tonsil)<br/> People with primary cancer of the head and neck where &gt; 50% of cases had oral/oropharynx cancer. If separate oral/oropharynx data are available they will be used to the exclusion of the combined head and neck cancer data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lip (ICD‐O: C00) cancers</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parotid gland (ICD‐O: C07), unspecified major salivary gland (ICD‐O: C08)<br/> and thyroid gland (ICD‐O: C73.9) cancers<br/> Nasopharynx (ICD‐O: C11), hypopharynx (ICD‐O: C13), larynx (ICD‐O: C32), pyriform sinus (ICD‐O: C12.9), accessory sinuses (ICD‐O: C31), nasal cavity and middle ear (ICD‐O: C30) cancers<br/> In combined head and neck trials, these cancers will be included if they comprise &lt; 50% of the total cancer diagnoses of participants </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ICD‐O: International Classification of Diseases for Oncology.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of inclusion and exclusion criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome data from Koh 2013</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Docetaxel + cisplatin + cetuximab (n = 48)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Docetaxel + cisplatin (n = 44)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS (3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (n = 33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PFS (3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% (n = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (n = 25)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ITT: intention to treat; n: number of participants; OS: overall survival; PFS: progression‐free survival. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome data from Koh 2013</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse event outcomes: comparison 1: monoclonal antibodies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (MH, 95% CI, P value)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity (P value; I<sup>2</sup>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1.6 Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1417</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not estimable due to high heterogeneity (P value = 0.0009; I<sup>2</sup> = 86%) between subgroups (cetuximab; nimotuzumab), and within the cetuximab subgroup (P value = 0.0002) I<sup>2</sup> = 93%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.96 to 1.51) (random effects) P value = 0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.07; I<sup>2</sup> = 58% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1.7 Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.92 to 1.03) (fixed effect) P value = 0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.60; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.83 to 1.04) (fixed effect) P value = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.26; I<sup>2</sup> = 26% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1.8 Xerostomia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.91 to 1.04) (fixed effect) P value = 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.61; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.36 (0.80 to 2.31) (fixed effect) P value = 0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.60; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>1.9 Skin toxicity/ acneiform rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value &lt; 0.00001; I<sup>2</sup> = 99.3%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (cetuximab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.56 (5.35 to 8.03) (fixed effect) P value &lt; 0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value = 0.080; I<sup>2</sup> = 66% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (nimotuzumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.85 to 1.31) P value = 0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value = 0.005; I<sup>2</sup> = 87.5%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (cetuximab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.72 (8.33 to 37.73) (fixed effect) P value &lt; 0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value = 0.56; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (nimotuzumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.01 to 4.05) P value = 0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; MH: Mantel‐Haenszel.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse event outcomes: comparison 1: monoclonal antibodies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse event outcomes: comparison 2: tyrosine kinase inhibitors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (MH, 95% CI, P value)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity (P value; I<sup>2</sup>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>2.5 Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.94 to 1.11) (fixed effect) P value = 0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.44; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22 (0.96 to 1.56) (fixed effect) P value = 0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.53; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>2.6 Skin toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value &lt; 0.00001; I<sup>2</sup> = 95.5%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (gefitinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.82 to 1.28) (fixed effect) P value = 0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value = 0.42; I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (lapatinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.02 (1.23 to 3.32) P value = 0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (erlotinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.57 (3.60 to 12.00) P value &lt; 0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25 (0.54 to 2.88) (random effects) P value = 0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.09; I<sup>2</sup> = 54% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>2.7 Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable due to significant difference between subgroups (P value = 0.007; I<sup>2</sup> = 86.2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (gefitinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.98 to 1.11) P value = 0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (lapatinib)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.53 (2.18 to 110.55) P value = 0.006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.83 to 1.49) (fixed effect) P value = 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.53; I<sup>2</sup> = 0% </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; MH: Mantel‐Haenszel.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse event outcomes: comparison 2: tyrosine kinase inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Outcome data from Bier 1981</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BCG‐cell wall preparation + surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Surgery alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall survival (3 years)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrence (3 years)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/10</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>BCG: Bacillus Calmette‐Guérin.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Outcome data from Bier 1981</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcome data from Mantovani 1998</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neoadjuvant chemotherapy (n = 17)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neoadjuvant chemotherapy + rIL‐2 (n = 16)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Locoregional control</p> <p>Complete response</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Locoregional control</p> <p>Partial response</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/13</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>rIL‐2: recombinant interleukin.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcome data from Mantovani 1998</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse event outcomes: comparison 3: immunotherapies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk ratio (MH, 95% CI, P value)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Heterogeneity (P value; I<sup>2</sup>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>3.3 Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.90 to 1.70) P value = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.40 (0.15 to 77.34) P value = 0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>3.4 Stomatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.47 (0.75 to 2.90) P value = 0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71 (0.33 to 8.83) P value = 0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>3.5 Leukopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.22 to 1.50) P value = 0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.04 to 3.26) P value = 0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.6 Increased temperature</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.13 to 3.30) P value = 0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.7 Moderate‐severe chills</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.00 (0.67 to 179.29) P value = 0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.8 Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.27 to 94.34) P value = 0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; MH: Mantel‐Haenszel.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse event outcomes: comparison 3: immunotherapies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/full#CD010341-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010341-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Monoclonal antibodies (mAb)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival (5 years) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 mAb therapy + radiotherapy (RT) vs. RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 mAb therapy + chemoradiotherapy (CRT) vs. CRT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Locoregional control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 mAb therapy + RT vs. RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 mAb therapy + RT vs. RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.54, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 mAb therapy + CRT vs. CRT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Monoclonal antibodies (mAb)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010341-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tyrosine kinase inhibitors (TKI)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.62, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TKI + chemoradiotherapy (CRT) vs. CRT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.62, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Locoregional control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.53, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 TKI + CRT vs. CRT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.53, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 TKI + radiotherapy (RT) vs. RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.61, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 TKI + CRT vs. CRT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tyrosine kinase inhibitors (TKI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010341-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Immunotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Surgery ± radiotherapy (RT) + rIL‐2 vs. surgery ± RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Surgery ± RT + rIL‐2 vs. surgery ± RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.43, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Immunotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0014"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: monoclonal antibodies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specified adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p><b>Ang 2014</b> </p> <p>Comparison: mAb</p> <p>(CRT + cetuximab vs. CRT (no placebo))</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Acute period</b> : ≤ 90 days from start of RT (Gp A n = 444; Gp B n = 447) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 431 (97%);<br/> Grades 3‐4: n = 395 (89%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 434 (97%);<br/> Grades 3‐4: n = 389 (87%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 364 (82%);<br/> Grades 3‐4: n = 235 (53%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 384 (86%);<br/> Grades 3‐4: n = 255 (57%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 364 (82%);<br/> Grades 3‐4: n = 191 (43%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 322 (72%);<br/> Grades 3‐4: n = 147 (33%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction outside portal</b> (pruritus; dermatitis exfoliative NOS; acne NOS; nail disorder NOS) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 364 (82%);<br/> Grades 3‐4: n = 89 (20%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 63 (14%);<br/> Grades 3‐4: n = 4 (1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction inside portal</b> (radiation dermatitis NOS; radiation recall syndrome) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 346 (78%);<br/> Grades 3‐4: n = 111 (25%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 353 (79%);<br/> Grades 3‐4: n = 67 (15%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 289 (65%);<br/> Grades 3‐4: n = 62 (14%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 268 (60%);<br/> Grades 3‐4: n = 40 (9%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Late period</b> : &gt; 90 days from start of RT (Gp A n = 415; Gp B n = 432) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 403 (97%);</p> <p>Grades 3‐4: n = 249 (60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 419 (97%);</p> <p>Grades 3‐4: n = 233 (54%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 357 (86%);</p> <p>Grades 3‐4: n = 154 (37%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 359 (83%);</p> <p>Grades 3‐4: n = 156 (36%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry mouth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 311 (75%);</p> <p>Grades 3‐4: n = 21 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 324 (75%);</p> <p>Grades 3‐4: n = 17 (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin fibrosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 311 (46%);</p> <p>Grades 3‐4: n = 8 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 190 (44%);</p> <p>Grades 3‐4: n = 4 (1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 170 (41%);</p> <p>Grades 3‐4: n = 12 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 194 (45%);</p> <p>Grades 3‐4: n = 13 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laryngeal oedema</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 166 (40%);</p> <p>Grades 3‐4: n = 17 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 181 (42%);</p> <p>Grades 3‐4: n = 13 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Bonner 2006</b> </p> <p>Comparison: mAb</p> <p>RT + cetuximab vs. RT (no placebo)</p> <p>(Gp A n = 208; Gp B n = 212)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 193 (93%);</p> <p>Grades 3‐5: n = 116 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 199 (94%);</p> <p>Grades 3‐5: n = 110 (52%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acneiform rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 181 (87%);</p> <p>Grades 3‐5: n = 35 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 21 (10%);</p> <p>Grades 3‐5: n = 2 (1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiation dermatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 179 (86%);</p> <p>Grades 3‐5: n = 48 (23%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 191 (90%);</p> <p>Grades 3‐5: n = 38 (18%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 175 (84%);</p> <p>Grades 3‐5: n = 23 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 153 (72%);</p> <p>Grades 3‐5: n = 15 (7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Xerostomia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 150 (72%);</p> <p>Grades 3‐5: n = 10 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 151 (71%);</p> <p>Grades 3‐5: n = 6 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 135 (65%);</p> <p>Grades 3‐5: n = 54 (26%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 134 (63%);</p> <p>Grades 3‐5: n = 64 (30%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><b>Koh 2013</b> </p> <p>Comparison: mAb</p> <p>(CRT + cetuximab vs. CRT (no placebo))</p> <p>Gp A n = 48; Gp B n = 44</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Partial narrative reporting for Gp A toxicities relating to attrition rationale in abstract: </p> <p>"Reason for incompletion in CDP arm included hypersensitivity (1), septic shock (1), skin rash (1), seizure (1), arterial thrombosis (1), unexplained death (1), unsatisfactory response (1), and withdrawal of informed consent (1)". No detail reported for Gp B. However, poster presented alongside abstract indicates similar frequency of Grade 3‐4 toxicities in both Gps </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutropenia</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 13 (27%)</p> <p>Grades 3‐4: n = 5 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 5 (11%)</p> <p>Grades 3‐4: n = 4 (9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anorexia</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 3 (6%)</p> <p>Grades 3‐4: n = 6 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (9%)</p> <p>Grades 3‐4: n = 4 (9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (8%)</p> <p>Grades 3‐4: n = 9 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 0 (0%)</p> <p>Grades 3‐4: n = 3 (7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile neutropenia</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 7 (%)</p> <p>Grades 3‐4: n = 3 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (9%)</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin toxicity</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 3 (6%)</p> <p>Grades 3‐4: n = 4 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 0 (0%)</p> <p>Grades 3‐4: n = 1 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhoea</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (8%)</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 3 (7%)</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Reddy 2014</b> </p> <p>Comparison: mAb</p> <p>CRT + nimotuzumab vs. CRT vs. RT + nimotuzumab vs. RT</p> <p>(Gp A n = 23; Gp B n = 23; Gp C n = 23; Gp D n = 23)</p> <p>**Note: control arm mucositis events Gp D n = 27 (+4 than Gp n), therefore, all grade mucositis data not used in analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 44 (96%);</p> <p>Grade 3: n = 21 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: <i>n = 49 (106%)** </i> ; </p> <p>Grade 3: n = 21 (46%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 37 (80%);</p> <p>Grade 3: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 35 (76%);</p> <p>Grade 3: n = 2 (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 34 (74%);</p> <p>Grade 3: n = 1 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (65%);</p> <p>Grade 3: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Salivary gland disorder</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 27 (59%);</p> <p>Grade 3: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (63%);</p> <p>Grade 3: n = 2 (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 16 (35%);</p> <p>Grade 3: n = 5 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 16 (35%);</p> <p>Grade 3: n = 1 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Candidiasis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 13 (28%);</p> <p>Grade 3: n = 5 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 19 (41%);</p> <p>Grade 3: n = 7 (15%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Rodriguez 2010</b> </p> <p>Comparison: mAb</p> <p>RT + nimotuzumab vs. RT + placebo</p> <p>(Gp A n = 54; Gp B n = 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30 (58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 11 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 9 (17%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry mouth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 9 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 12 (23%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry radio‐dermatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 6 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 6 (12%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Odynophagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 4 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 6 (12%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CRT: chemoradiotherapy; Gp: group; mAb: monoclonal antibody; NOS: not otherwise specify; RT: radiotherapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: monoclonal antibodies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0015"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: immunotherapies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Specified adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Stefani 2002</b> </p> <p>Comparison: interleukin</p> <p>rIL‐2 + RT + surgery vs. RT + surgery (no placebo)</p> <p>(Gp A n = 100; Gp B n = 101)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Narrative commentary only:</p> <p>"Complication and toxicity rates for the surgery arm and the surgery plus radiotherapy arm were the same in the control group and in the rIL‐2 group. </p> <p>Postoperative radiotherapy originates well‐known side effects, but they were independent of the preoperative rIL‐2 treatment. [...] </p> <p>Neoadjuvant rIL‐2 injections did not complicate the surgical treatment, and adjuvant rIL‐2 injections did not increase distant side effects due to previous surgery or radiotherapy" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Mantovani 1998</b> </p> <p>Comparison: interleukin</p> <p>rIL‐2 + CRT ± surgery vs. CRT ± surgery (no placebo)</p> <p>(Gp A n = 14; Gp B n = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 13 (93%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 12 (75%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stomatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 9 (64%);</p> <p>Grades 3‐4: n = 3 (21%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 7 (44%);</p> <p>Grades 3‐4: n = 2 (13%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leukopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 4 (29%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 8 (50%);</p> <p>Grades 3‐4: n = 3 (19%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 6 (43%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 0 (0%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 2 (14%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 3 (19%);</p> <p>Grades 3‐4: n = 1 (6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 3 (21%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 2 (13%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Bier 1981</b> </p> <p>Comparison:</p> <p>BCG‐CWP + surgery vs. surgery (no placebo)</p> <p>(Gp A n = 12; Gp B n = 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Increased temperature</b> <br/> <b>(&gt; 3 to ≤ 14 days post treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 3 (25%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate‐severe chills</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 5 (42%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gastrointestinal complaints (including nausea/vomiting)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 0 (0%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>BCG‐CWP: Bacillus Calmette‐Guérin ‐ cell wall preparation; Gp: group; n: number of participants; rIL‐2: recombinant interleukin; RT: radiotherapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: immunotherapies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0016"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: tyrosine kinase inhibitors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specified adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Gregoire 2011</b> </p> <p>Comparison: TKI</p> <p>(CRT + gefitinib (250/500 mg) vs.<br/> CRT + placebo) (concomitant phase<br/> only: Gp A n = 110 (Gps B+C+D+E); </p> <p>Gp B n = 116 (Gps A+F+G))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 96 (87%);</p> <p>Grades 3‐5: n = 51 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 98 (84%);</p> <p>Grades 3‐5: n = 42 (36%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 50 (45%);</p> <p>Grades 3‐5: n = 4 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 55 (47%);</p> <p>Grades 3‐5: n = 3 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 56 (51%);</p> <p>Grades 3‐5: n = 6 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 52 (45%);</p> <p>Grades 3‐5: n = 9 (8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (26%);</p> <p>Grades 3‐5: n = 5 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 43 (37%);</p> <p>Grades 3‐5: n = 13 (11%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry mouth (xerostomia)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 33 (30%);<br/> Grades 3‐5: n = 1 (1%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (26%);</p> <p>Grades 3‐5: n = 2 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiation skin injury</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (26%);</p> <p>Grades 3‐4: n = 2 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (25%);</p> <p>Grades 3‐5: n = 4 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Harrington 2013</b> </p> <p>Comparison: TKI</p> <p>(CRT + lapatinib vs. CRT + placebo)</p> <p>Gp A n = 34; Gp B n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 16 (46%);</p> <p>Grade 3: n = 2 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 1 (3%);</p> <p>Grade 3: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 10 (29%);</p> <p>Grade 3: n = 3 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 5 (16%);</p> <p>Grade 3: n = 1 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other skin reactions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 15 (43%);</p> <p>Grade 3: n = 2 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 7 (23%);</p> <p>Grade 3: n = 5 (16%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Martins 2013</b> <br/> Comparison: TKI (CRT + erlotinib vs.<br/> CRT (no placebo)) </p> <p>(Gp A n = 95; Gp B n = 96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 50 (53%);</p> <p>Grades 3‐4: n = 18 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 54 (56%);</p> <p>Grades 3‐4: n = 18 (19%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 46 (48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 41 (43%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 65 (68%);</p> <p>Grade 3: n = 12 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 10 (10%);</p> <p>Grade 3: n = 2 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38 (40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32 (33%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haematological</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 15 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 25 (26%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 7 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 5 (5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Singh 2013</b> </p> <p>Comparison TKI</p> <p>RT + gefitinib vs. RT (no placebo)</p> <p>(Gp A n = 30; Gp B n = 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 21 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 19 (63%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 12 (40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 11 (36%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CRT: chemoradiotherapy; Gp: group; n: number of participants; TKI: tyrosine kinase inhibitor. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: tyrosine kinase inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0014"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: monoclonal antibodies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specified adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p><b>Ang 2014</b> </p> <p>Comparison: mAb</p> <p>(CRT + cetuximab vs. CRT (no placebo))</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Acute period</b> : ≤ 90 days from start of RT (Gp A n = 444; Gp B n = 447) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 431 (97%);<br/> Grades 3‐4: n = 395 (89%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 434 (97%);<br/> Grades 3‐4: n = 389 (87%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 364 (82%);<br/> Grades 3‐4: n = 235 (53%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 384 (86%);<br/> Grades 3‐4: n = 255 (57%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 364 (82%);<br/> Grades 3‐4: n = 191 (43%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 322 (72%);<br/> Grades 3‐4: n = 147 (33%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction outside portal</b> (pruritus; dermatitis exfoliative NOS; acne NOS; nail disorder NOS) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 364 (82%);<br/> Grades 3‐4: n = 89 (20%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 63 (14%);<br/> Grades 3‐4: n = 4 (1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction inside portal</b> (radiation dermatitis NOS; radiation recall syndrome) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 346 (78%);<br/> Grades 3‐4: n = 111 (25%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 353 (79%);<br/> Grades 3‐4: n = 67 (15%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 289 (65%);<br/> Grades 3‐4: n = 62 (14%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 268 (60%);<br/> Grades 3‐4: n = 40 (9%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Late period</b> : &gt; 90 days from start of RT (Gp A n = 415; Gp B n = 432) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 403 (97%);</p> <p>Grades 3‐4: n = 249 (60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 419 (97%);</p> <p>Grades 3‐4: n = 233 (54%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 357 (86%);</p> <p>Grades 3‐4: n = 154 (37%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 359 (83%);</p> <p>Grades 3‐4: n = 156 (36%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry mouth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 311 (75%);</p> <p>Grades 3‐4: n = 21 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 324 (75%);</p> <p>Grades 3‐4: n = 17 (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin fibrosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 311 (46%);</p> <p>Grades 3‐4: n = 8 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 190 (44%);</p> <p>Grades 3‐4: n = 4 (1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 170 (41%);</p> <p>Grades 3‐4: n = 12 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 194 (45%);</p> <p>Grades 3‐4: n = 13 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laryngeal oedema</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 166 (40%);</p> <p>Grades 3‐4: n = 17 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 181 (42%);</p> <p>Grades 3‐4: n = 13 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Bonner 2006</b> </p> <p>Comparison: mAb</p> <p>RT + cetuximab vs. RT (no placebo)</p> <p>(Gp A n = 208; Gp B n = 212)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 193 (93%);</p> <p>Grades 3‐5: n = 116 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 199 (94%);</p> <p>Grades 3‐5: n = 110 (52%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acneiform rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 181 (87%);</p> <p>Grades 3‐5: n = 35 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 21 (10%);</p> <p>Grades 3‐5: n = 2 (1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiation dermatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 179 (86%);</p> <p>Grades 3‐5: n = 48 (23%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 191 (90%);</p> <p>Grades 3‐5: n = 38 (18%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight loss</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 175 (84%);</p> <p>Grades 3‐5: n = 23 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 153 (72%);</p> <p>Grades 3‐5: n = 15 (7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Xerostomia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 150 (72%);</p> <p>Grades 3‐5: n = 10 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 151 (71%);</p> <p>Grades 3‐5: n = 6 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 135 (65%);</p> <p>Grades 3‐5: n = 54 (26%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 134 (63%);</p> <p>Grades 3‐5: n = 64 (30%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><b>Koh 2013</b> </p> <p>Comparison: mAb</p> <p>(CRT + cetuximab vs. CRT (no placebo))</p> <p>Gp A n = 48; Gp B n = 44</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Partial narrative reporting for Gp A toxicities relating to attrition rationale in abstract: </p> <p>"Reason for incompletion in CDP arm included hypersensitivity (1), septic shock (1), skin rash (1), seizure (1), arterial thrombosis (1), unexplained death (1), unsatisfactory response (1), and withdrawal of informed consent (1)". No detail reported for Gp B. However, poster presented alongside abstract indicates similar frequency of Grade 3‐4 toxicities in both Gps </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutropenia</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 13 (27%)</p> <p>Grades 3‐4: n = 5 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 5 (11%)</p> <p>Grades 3‐4: n = 4 (9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anorexia</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 3 (6%)</p> <p>Grades 3‐4: n = 6 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (9%)</p> <p>Grades 3‐4: n = 4 (9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (8%)</p> <p>Grades 3‐4: n = 9 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 0 (0%)</p> <p>Grades 3‐4: n = 3 (7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile neutropenia</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 7 (%)</p> <p>Grades 3‐4: n = 3 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (9%)</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin toxicity</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 3 (6%)</p> <p>Grades 3‐4: n = 4 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 0 (0%)</p> <p>Grades 3‐4: n = 1 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhoea</b> </p> <p>CRT induction</p> <p>Concurrent CRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 4 (8%)</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 3 (7%)</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Reddy 2014</b> </p> <p>Comparison: mAb</p> <p>CRT + nimotuzumab vs. CRT vs. RT + nimotuzumab vs. RT</p> <p>(Gp A n = 23; Gp B n = 23; Gp C n = 23; Gp D n = 23)</p> <p>**Note: control arm mucositis events Gp D n = 27 (+4 than Gp n), therefore, all grade mucositis data not used in analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 44 (96%);</p> <p>Grade 3: n = 21 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: <i>n = 49 (106%)** </i> ; </p> <p>Grade 3: n = 21 (46%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 37 (80%);</p> <p>Grade 3: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 35 (76%);</p> <p>Grade 3: n = 2 (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 34 (74%);</p> <p>Grade 3: n = 1 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (65%);</p> <p>Grade 3: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Salivary gland disorder</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 27 (59%);</p> <p>Grade 3: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (63%);</p> <p>Grade 3: n = 2 (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 16 (35%);</p> <p>Grade 3: n = 5 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 16 (35%);</p> <p>Grade 3: n = 1 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Candidiasis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 13 (28%);</p> <p>Grade 3: n = 5 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 19 (41%);</p> <p>Grade 3: n = 7 (15%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Rodriguez 2010</b> </p> <p>Comparison: mAb</p> <p>RT + nimotuzumab vs. RT + placebo</p> <p>(Gp A n = 54; Gp B n = 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30 (58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 11 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 9 (17%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry mouth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 9 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 12 (23%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry radio‐dermatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 6 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 6 (12%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Odynophagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 4 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 6 (12%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CRT: chemoradiotherapy; Gp: group; mAb: monoclonal antibody; NOS: not otherwise specify; RT: radiotherapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: monoclonal antibodies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0015"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: immunotherapies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Specified adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>De Stefani 2002</b> </p> <p>Comparison: interleukin</p> <p>rIL‐2 + RT + surgery vs. RT + surgery (no placebo)</p> <p>(Gp A n = 100; Gp B n = 101)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Narrative commentary only:</p> <p>"Complication and toxicity rates for the surgery arm and the surgery plus radiotherapy arm were the same in the control group and in the rIL‐2 group. </p> <p>Postoperative radiotherapy originates well‐known side effects, but they were independent of the preoperative rIL‐2 treatment. [...] </p> <p>Neoadjuvant rIL‐2 injections did not complicate the surgical treatment, and adjuvant rIL‐2 injections did not increase distant side effects due to previous surgery or radiotherapy" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Mantovani 1998</b> </p> <p>Comparison: interleukin</p> <p>rIL‐2 + CRT ± surgery vs. CRT ± surgery (no placebo)</p> <p>(Gp A n = 14; Gp B n = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 13 (93%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 12 (75%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stomatitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 9 (64%);</p> <p>Grades 3‐4: n = 3 (21%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 7 (44%);</p> <p>Grades 3‐4: n = 2 (13%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leukopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 4 (29%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 8 (50%);</p> <p>Grades 3‐4: n = 3 (19%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 6 (43%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 0 (0%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 2 (14%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 3 (19%);</p> <p>Grades 3‐4: n = 1 (6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 3 (21%);</p> <p>Grades 3‐4: n = 1 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 2 (13%);</p> <p>Grades 3‐4: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Bier 1981</b> </p> <p>Comparison:</p> <p>BCG‐CWP + surgery vs. surgery (no placebo)</p> <p>(Gp A n = 12; Gp B n = 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Increased temperature</b> <br/> <b>(&gt; 3 to ≤ 14 days post treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 3 (25%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate‐severe chills</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 5 (42%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gastrointestinal complaints (including nausea/vomiting)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 0 (0%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>BCG‐CWP: Bacillus Calmette‐Guérin ‐ cell wall preparation; Gp: group; n: number of participants; rIL‐2: recombinant interleukin; RT: radiotherapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: immunotherapies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010341-tbl-0016"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: tyrosine kinase inhibitors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specified adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Gregoire 2011</b> </p> <p>Comparison: TKI</p> <p>(CRT + gefitinib (250/500 mg) vs.<br/> CRT + placebo) (concomitant phase<br/> only: Gp A n = 110 (Gps B+C+D+E); </p> <p>Gp B n = 116 (Gps A+F+G))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 96 (87%);</p> <p>Grades 3‐5: n = 51 (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 98 (84%);</p> <p>Grades 3‐5: n = 42 (36%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 50 (45%);</p> <p>Grades 3‐5: n = 4 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 55 (47%);</p> <p>Grades 3‐5: n = 3 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 56 (51%);</p> <p>Grades 3‐5: n = 6 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 52 (45%);</p> <p>Grades 3‐5: n = 9 (8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (26%);</p> <p>Grades 3‐5: n = 5 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 43 (37%);</p> <p>Grades 3‐5: n = 13 (11%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry mouth (xerostomia)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 33 (30%);<br/> Grades 3‐5: n = 1 (1%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (26%);</p> <p>Grades 3‐5: n = 2 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiation skin injury</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (26%);</p> <p>Grades 3‐4: n = 2 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 29 (25%);</p> <p>Grades 3‐5: n = 4 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Harrington 2013</b> </p> <p>Comparison: TKI</p> <p>(CRT + lapatinib vs. CRT + placebo)</p> <p>Gp A n = 34; Gp B n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 16 (46%);</p> <p>Grade 3: n = 2 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 1 (3%);</p> <p>Grade 3: n = 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 10 (29%);</p> <p>Grade 3: n = 3 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 5 (16%);</p> <p>Grade 3: n = 1 (3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other skin reactions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 15 (43%);</p> <p>Grade 3: n = 2 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 7 (23%);</p> <p>Grade 3: n = 5 (16%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Martins 2013</b> <br/> Comparison: TKI (CRT + erlotinib vs.<br/> CRT (no placebo)) </p> <p>(Gp A n = 95; Gp B n = 96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 50 (53%);</p> <p>Grades 3‐4: n = 18 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 54 (56%);</p> <p>Grades 3‐4: n = 18 (19%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 46 (48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 41 (43%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rash</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 65 (68%);</p> <p>Grade 3: n = 12 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 10 (10%);</p> <p>Grade 3: n = 2 (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38 (40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32 (33%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haematological</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 15 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 25 (26%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 7 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3‐4: n = 5 (5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Singh 2013</b> </p> <p>Comparison TKI</p> <p>RT + gefitinib vs. RT (no placebo)</p> <p>(Gp A n = 30; Gp B n = 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mucositis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 21 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 19 (63%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Skin reaction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 12 (40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All grades: n = 30 (100%);</p> <p>Grades 3‐4: n = 11 (36%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CRT: chemoradiotherapy; Gp: group; n: number of participants; TKI: tyrosine kinase inhibitor. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: tyrosine kinase inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010341.pub2/references#CD010341-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010341.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010341-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010341-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010341-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010341-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010341-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD010341-note-0022">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010341\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010341\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010341\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010341\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010341\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010341.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010341.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010341.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010341.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010341.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726353383"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010341.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726353387"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010341.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e918f6b1d9368',t:'MTc0MDcyNjM1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 